L’iboga, un champ
de recherche vivant.

Dossier documentaire · 14 octobre 2026

Des signaux prometteurs.
Des preuves à consolider.

L’iboga est une plante ; l’ibogaïne est l’un de ses alcaloïdes ; la noribogaïne est notamment un métabolite de l’ibogaïne. Les extraits végétaux, les molécules purifiées et les analogues de synthèse sont des objets de recherche différents. Leurs résultats ne sont pas interchangeables.

Une lecture critique de la littérature

Les études qui structurent
la discussion.

Cette sélection commentée met en regard les résultats et leurs limites. Une publication peut comporter plusieurs analyses d’une même cohorte : leur nombre ne représente donc pas le nombre d’essais indépendants.

Notre proposition de travail

Les pistes à renforcer.

Ces priorités proposées pour le futur laboratoire découlent des lacunes de la littérature et des besoins de caractérisation des produits. Elles constituent une feuille de route à discuter avec des partenaires scientifiques.

Index international · 691 références

Explorer la bibliothèque.

Un index documentaire pour retrouver les publications sur l’ibogaïne, la noribogaïne, Tabernanthe iboga, le tabernanthalog et la 18-méthoxycoronaridine. Les références indexées ne sont pas toutes des études cliniques ni toutes évaluées par les pairs.

691 références

• Voacangine/coronaridine hydroxylases catalyze C19-hydroxylation in iboga alkaloid synthesis.2026 · Lopez-Vazquez AL, Durand M, Birer-Williams C, Perdereau E, Marais E, Perrot T, Oudin A, Lanoue A, St-Pierre B, Papon N, Massiot G, Sun C, Besseau S, Courdavault V.Planta · MED 41870636 · DOI 10.1007/s00425-026-04987-z
• US speeds up research into mind-altering drugs - including mysterious 'ibogaine'.2026 · Kozlov M.Nature · MED 42020588 · DOI 10.1038/d41586-026-01286-1
• U.S. Veterans and Psychedelics: Prevalence of Use and Policy Preferences.2026 · Priest M, Schell TL, Senator B, Kilmer B.Rand Health Q · MED 42824827 · DOI 10.7249/rhq-13-04-08
• Tuning reductase activity in monoterpene indole alkaloid biosynthesis.2026 · Carr SC, Wu S, Gase K, Nakamura Y, Kamileen MO, Kunert M, Heinicke S, Kang M, Grabe V, Caputi L, O'Connor SE.Proc Natl Acad Sci U S A · MED 42296364 · DOI 10.1073/pnas.2605425123
• Toward a nuanced framework for the medical development of ibogaine and its analogues and derivatives: implications for psychopharmacology.2026 · Verrico CD, Averill LA, Moore CJ, McGuire AL, Kosten TR, Salas R.Expert Opin Drug Discov · MED 42400152 · DOI 10.1080/17460441.2026.2693144
• Thirty Years of Ibogaine Research: A Literature Review on Clinical Perspectives.2026 · Kervadec E, Bezo A, Serreau R, Strika-Bruneau L, Fauvel B, Amirouche A, Benyamina A, Romeo B.J Clin Psychopharmacol · MED 42228481 · DOI 10.1097/jcp.0000000000002197
• The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review.2026 · Giaffone de Paiva Ferreira F, Fernandes JAB, Filev R, da Silveira DX, Fidalgo TM.J Psychopharmacol · MED 42363614 · DOI 10.1177/02698811261453850
• Sustained abstinence in severe ketamine use disorder following ibogaine treatment case report.2026 · Pérez Rosal SR, Faber SC, Backmund M.Front Psychiatry · MED 42548882 · DOI 10.3389/fpsyt.2026.1846320
• Structure-Dependent Antioxidant Activity of Ibogalogs: Impact of Methoxy Group Position on the Protective Activity in Model and Synaptosomal Lipid Membranes.2026 · Kazmierska-Grebowska P, Grebowski J, Żebrowski M, DiLabio GA, Ciesielski O, Balcerczyk A, Arias HR, Litwinienko G.ACS Chem Neurosci · MED 41843582 · DOI 10.1021/acschemneuro.6c00087
• Selective Delivery of Anticancer Natural G-Quadruplex Ligands by the AT11 Aptamer for Gastric Cancer Treatment.2026 · Platella C, Trajkovski M, Brancaccio M, Di Palma R, Calcaterra A, Mori M, Falco G, Plavec J, Montesarchio D.J Med Chem · MED 41397894 · DOI 10.1021/acs.jmedchem.5c02521
• Rare but relevant: Ibogaine and cardiovascular complications-prolonged QT interval and ventricular arrhythmias.2026 · Brunt TM.Addiction · MED 41560340 · DOI 10.1111/add.70319
• Psychedelics, entactogens and psychoplastogens for depression and related disorders.2026 · Hoyer D.Br J Pharmacol · MED 40518133 · DOI 10.1111/bph.70088
• Psychedelics and Ibogaine "Pain Medications" at the Pharmacy Counter: Implications for Pharmacy Practice.2026 · Breve F, Berenato FJ, Pergolizzi JV, Varrassi G, Raffa RB.J Pain Res · MED 42438816 · DOI 10.2147/jpr.s629049
• Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations.2026 · Marazziti D, Gambini M, Gurrieri R, Russomanno G, Sità G, Pescini E, Digiuseppe FR, Mucci F.Expert Opin Pharmacother · MED 41944071 · DOI 10.1080/14656566.2026.2654682
• Psychedelic Modulation of Excitation/Inhibition Balance: A Dual-Phase Neurodevelopmental Model.2026 · Kandilakis CL, Papatheodoropoulos C.ACS Chem Neurosci · MED 41498818 · DOI 10.1021/acschemneuro.5c00892
• Psilocybin and Ibogaine in Cocaine-Seeking: Extinction Enhancement Without Relapse Prevention.2026 · Koutrouli IRA, Brejtr V, Schwendt M, Witek K, Charalambous C, Aleksič K, Miniariková N, Lhotková E, Toman M, Nikolič M, Jurok R, Cihlářová P, Mazoch V, Ryšánek P, Kuchař M, Šíchová K, Páleníček T.Addict Biol · MED 41780506 · DOI 10.1111/adb.70111
• Oxa-noribogaine reduces alcohol drinking through aversion learning and by altering glutamatergic activity in the mPFC2026 · Meinhardt M, Skorodumov I, Walter F, Akan M, Buchborn T, PRIEULT YL, Urban M, Spanagel R, von Ammon L, Hopf C, Kalinichenko L, Mueller C, Winter C, Hadar R, Gül AZ, Massuda B, Hildebrandt M, Domi E, Keshishian A, Ciccocioppo R, Sames D, Havel V, Woods L, Beeson A.Support non renseigné dans l’index · PPR PPR1172222 · DOI 10.21203/rs.3.rs-9103509/v1
• Oral 18-methoxycoronaridine activity in simian and murine <i>Leishmania amazonensis</i> infection.2026 · Delorenzi JC, Melo TS, Silveira FT, Carneiro LA, Campos MB, Cunha MR, Ricci EL, Fukushima AR, Hurst SL, Freeman SM, Almeida-Saavedra MS, Mourad AM, Sacchelli-Ramos C, Delorenzi LBO, Delorenzi GB, Saraiva EM.Front Pharmacol · MED 42038284 · DOI 10.3389/fphar.2026.1780255
• Novel pharmacotherapies for opioid use disorder and opioid withdrawal.2026 · Shen MR, Owusu-Boaitey K, Murphy ZD, Rains AN, Wang PR, Zhou DW, Suzuki J.Front Psychiatry · MED 42755825 · DOI 10.3389/fpsyt.2026.1909149
• Non-adherence to registration further undermines the methodologically weak Stanford University Magnesium-Ibogaine Study.2026 · Gorman DM.Int J Drug Policy · MED 42330793 · DOI 10.1016/j.drugpo.2026.105408
• Neurorestorative properties of ibogaine: linking multi-receptor affinities to remyelination and metabolic restoration.2026 · Calvey T, Govender D, Owen GR, Tumba N, Lang D, Lerer B, Stein DJ, Shoptaw S.Acta Neuropsychiatr · MED 41679899 · DOI 10.1017/neu.2026.10059
• Neural Correlates of Ibogaine: Evidence From Functional Neuroimaging of Military Veterans.2026 · Sridhar M, Azeez A, Geoly AD, Lissemore JI, Faerman A, Cherian K, Buchanan DM, Hunegnaw S, Keynan JN, Kratter IH, Rolle C, Saggar M, Williams NR.Biol Psychiatry Cogn Neurosci Neuroimaging · MED 41687815 · DOI 10.1016/j.bpsc.2026.02.001
• Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans.2026 · Brown RE, Lissemore JI, Shinozuka KF, Coetzee JP, Faerman A, Olash CA, Geoly AD, Buchanan DM, Cherian KN, Chaiken A, Shamma A, Sridhar M, Hunegnaw SA, Johnson ND, Rolle CE, Adamson MM, Williams NR.J Affect Disord · MED 41265656 · DOI 10.1016/j.jad.2025.120722
• Letter to the Editor for "Evaluating Pharmacogenomic Prescription Data in the Military Health System": Medication-Induced CYP2D6 Inhibition Reveals a Screening Gap in Proxy-Defined Ibogaine Candidates.2026 · Green J, Hartin P, Ljubic B, Schulewski M, Parrott JS, Tafuto B.Mil Med · MED 42800901 · DOI 10.1093/milmed/usag436
• Indole Alkaloids as Biased Opioid Receptor Modulators.2026 · Grundmann O, Henderson A.Pharmaceuticals (Basel) · MED 41901244 · DOI 10.3390/ph19030397
• Indole Alkaloids as Biased Opioid Receptor Modulators2026 · Grundmann O, Henderson A.Support non renseigné dans l’index · PPR PPR1148877 · DOI 10.20944/preprints202601.2298.v1
• Indication-stratified mortality risk of ibogaine treatment under contemporary safety protocols: a multisite analysis of 19,071 patients and updated systematic review of fatalities2026 · Arns M, Shinozuka K, Barsuglia J.Support non renseigné dans l’index · PPR PPR1253707 · DOI 10.21203/rs.3.rs-9966269/v1
• Increased cortical thickness and decreased brain age among special operations veterans with blast TBI after a magnesium-ibogaine protocol.2026 · Geoly AD, Coetzee JP, Buchanan DM, Struckmann W, Kim B, Sridhar M, Azeez A, Lissemore JI, Cherian K, Faerman A, Keynan JN, Singal P, Shanbour A, Bandeira ID, Kratter IH, Adamson MM, Saggar M, Rolle C, Williams NR.iScience · MED 41883580 · DOI 10.1016/j.isci.2026.115121
• Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan.2026 · Raffa RB.Cureus · MED 42733721 · DOI 10.7759/cureus.116178
• Ibogalogs reduce acute and chronic headache-like behaviours in rodents by different co-modulatory mechanisms involving 5-HT 1 and 5-HT 2 receptor subtypes2026 · Chen S, Arias HR, Abraham A, Wacker D, Largent-Milnes TM.Support non renseigné dans l’index · PPR PPR1322267 · DOI 10.21203/rs.3.rs-10924055/v1
• Ibogalogs and their pyridoindole homologs activate or inhibit the 5-HT<sub>2B</sub> receptor by modulating the distance between transmembrane segments TM3 and TM6 in the orthosteric site.2026 · Arias HR, Rudin D, Ren X, Liechti ME, Huang N.Eur J Pharmacol · MED 42092485 · DOI 10.1016/j.ejphar.2026.178918
• Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives in the Treatment of Substance Use Disorders-A Scoping Review.2026 · Esperança MP, Gomes NGM, Campos MG.Molecules · MED 41683522 · DOI 10.3390/molecules31030545
• Ibogaine is associated with reorganization of high-beta brain networks in veterans with post-traumatic stress disorder2026 · Shinozuka K, Rosso M, Chaiken A, Lissemore JI, Jones R, Descalco N, Subramani V, Belgers M, Cherian KN, Arns M, Momi D, Airan RD, Bonetti L, Schellekens A, Adamson MM, Keller CJ, Rolle C.Support non renseigné dans l’index · PPR PPR1218354 · DOI 10.64898/2026.03.20.713241
• Ibogaine induces juvenile-like plasticity and modulates functional and structural regulators of plasticity in the adult mouse visual cortex.2026 · Acuña A, Billeri F, Totaro V, Carrera I, Mesa JM, Pizzorusso T, Rossi FM.BMC Neurosci · MED 42129626 · DOI 10.1186/s12868-026-01005-6
• Ibogaine in the Vet Brain: Changes in Brain Metabolism and Connectivity After Ibogaine Administration in Veterans With Traumatic Brain Injury.2026 · Fonzo GA.Biol Psychiatry Cogn Neurosci Neuroimaging · MED 42250921 · DOI 10.1016/j.bpsc.2026.04.005
• Ibogaine for Opioid Use Disorder: An Unrecognized Risk.2026 · Terasaki D, Sackett N, Monte A.J Addict Med · MED 41535993 · DOI 10.1097/adm.0000000000001645
• Ibogaine as a double-edged sword: Developmental cardiotoxicity and neurobehavioral alterations in zebrafish.2026 · de Oliveira AL, Abe FR, Dos Santos RG, Hallak JEC, de Oliveira DP.Behav Brain Res · MED 42595017 · DOI 10.1016/j.bbr.2026.116429
• From monotherapy to sequential models: An updated scoping review on ibogaine's role in treatment for psychiatric disorders.2026 · Sharma P, Kendrick J, Schram J, Stumo SM, Garscia A, Matthews DB.J Psychopharmacol · MED 42117212 · DOI 10.1177/02698811261443674
• Feasibility, safety and preliminary effects of ibogaine in patients with moderate and severe alcohol use disorder: a pilot, open-label study.2026 · Rocha JM, Maekawa RM, Reis JAS, Guerra LTL, Rossi GN, Rodrigues LS, Villanova B, Vicentini AB, de Paula CC, Bouso JC, Hallak JEC, Dos Santos RG.Trends Psychiatry Psychother · MED 42520175 · DOI 10.47626/2237-6089-2026-1437
• Extracellular flux analysis and proteomic profiling indicate ibogaine promotes synaptic plasticity and neural repair by a metabolic preconditioning mechanism2026 · Oulton MJ, Kasheke GDS, Meaney KA, Aubie-Arseneault RA, Pushparaj A, Dickinson JE, Hughes CS, Robertson GS.Support non renseigné dans l’index · PPR PPR1333003 · DOI 10.64898/2026.09.29.755437
• Exploring the Use of Ibogaine in Opioid Recovery: Insights from Lived Experience.2026 · Walker J, Deering D, Unger BH.J Psychoactive Drugs · MED 42171381 · DOI 10.1080/02791072.2026.2673843
• Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review.2026 · van der Meer PB, Schukking N, Dik M, van Reemst A, Fuentes JJ, Kaptein AA, Schoones JW, Verboeket S, de Waal MM, Goudriaan AE, Kramers C, Schellekens A, Bossong MG, Somers M, Batalla A.Psychedelic Med (New Rochelle) · MED 42130778 · DOI 10.1177/28314425251364182
• Dynamic Substates of the Default Mode Network Are Associated with Mystical Experiences and Clinical Outcomes after Magnesium-Ibogaine Treatment in Veterans with Traumatic Brain Injury2026 · Shinozuka K, Olash C, Han T, Azeez A, Sridhar M, Geoly AD, Daye C, Hunegnaw S, Cherian KN, Keynan JN, Brown RE, Buchanan DM, Coetzee JP, Kratter IH, Airan RD, Arns M, Adamson MM, Saggar M, Rolle C.Support non renseigné dans l’index · PPR PPR1284401 · DOI 10.64898/2026.07.20.26358512
• Development of Bioisosteres of Iboga Alkaloids: A Step-Economical Synthesis to Enhance the Antinociceptive and Anxiolytic Activity with Neuroprotective Effects.2026 · Gupta A, Bhattacharya T, Pratihar S, Parvage S, Sharma SN, Sarkar A, De A, Karmakar S, Dey S, Sinha S.ACS Pharmacol Transl Sci · MED 42130713 · DOI 10.1021/acsptsci.5c00301
• Development and validation of a UPLC-MS/MS method for real-time neuropharmacokinetic monitoring of iboga alkaloids in rat brain.2026 · McIntosh S, Maldonado I, Smith NC, Gadepalli RS, Rimoldi JM, Havel V, Sames D, Hemby SE.J Pharm Biomed Anal · MED 42364550 · DOI 10.1016/j.jpba.2026.117630
• Deciphering Ibogaine's Matrix Pharmacology: Multiple Transporter Modulation at Serotonin Synapses.2026 · Hwu C, Havel V, Westergaard X, Mendieta AM, Serrano IC, Hwu J, Walther D, Lankri D, Selinger TL, He K, Liu R, Shern TP, Sun S, Ma B, González B, Rodriguez L, Goodman HJ, Wu H, Sonders MS, Baumann MH, Carrera I, Sulzer D, Sames D.J Am Chem Soc · MED 41452009 · DOI 10.1021/jacs.5c06325
• Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series.2026 · Tabaac BJ, Carhart-Harris RL, Yung T.Front Pharmacol · MED 42318348 · DOI 10.3389/fphar.2026.1840956
• Cardiac Arrhythmia Associated with Psychoactive Drugs: An analysis of the FDA Adverse Event Reporting System2026 · Krantz MJ, Haigney MC, Southworth MR, Stockbridge N, Kao DP.Support non renseigné dans l’index · PPR PPR1317951 · DOI 10.64898/2026.09.08.26362577
• Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.2026 · Orsini DK, Wong S, Di Luch S, Chan B, Vasudeva S, Lovell GFM, Le GH, Jones BDM, Chisamore N, Mollica A, Johnson DE, Kaczmarek ES, Goel A, Burke MJ, Mansur R, McIntyre RS, Husain MI, Rosenblat JD.JAMA Psychiatry · MED 41984443 · DOI 10.1001/jamapsychiatry.2026.0255
• Beyond the Genomic Storm: Evaluating Tabernanthalog as a Potential Scaffold for Silent Neuroplasticity and Broad-Spectrum Therapy.2026 · Anchesi I, Raffaele I, Astorino MF, Lui M, Calabrò M, Cipriano GL.Int J Mol Sci · MED 41898671 · DOI 10.3390/ijms27062811
• An auxiliary protein tunes reductase activity in alkaloid biosynthesis2026 · Carr SC, Wu S, Gase K, Nakamura Y, Kamileen MO, Kunert M, Heinicke S, Kang M, Grabe V, Caputi L, O’Connor SE.Support non renseigné dans l’index · PPR PPR1213563 · DOI 10.64898/2026.04.21.719811
• Altered States of Consciousness and the Subconscious Mind: A Comprehensive Comparative Review of Disciplines, Neurobiological Mechanisms, Clinical Applications, and Philosophical Frameworks — Including Life Between Lives and Transpersonal Hypnotherapy2026 · Gallardo LM.Support non renseigné dans l’index · PPR PPR1175423 · DOI 10.20944/preprints202604.0415.v1
• Alpha-methyl-para-tyrosine and amphetamine ameliorate hyperactivity in a novel mouse model of dopamine transporter deficiency syndrome.2026 · Russo EE, Rezayof A, Wallace C, Williams EQ, Beerepoot P, Milenkovic M, Novalen M, Blundell A, Lipina TV, Locke J, Christian R, Finnie PSB, Edgar LJ, Tyndale RF, Watkins-Chow D, Ramsey AJ, Jones SR, Salahpour A.EMBO Mol Med · MED 41699258 · DOI 10.1038/s44321-026-00381-0
• Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT.2026 · Simonsson O, Bradley M, Black JC, Rockhill KM, Monte AA, Hendricks PS.JAMA Netw Open · MED 42809289 · DOI 10.1001/jamanetworkopen.2026.36756
• Activity of Nonhallucinogenic Ibogalogs on Chemotherapy-Induced Peripheral Neuropathic Pain in Mice.2026 · Younkin J, Koseli E, Buzzi B, Choi E, Honaker T, Davis RL, Manetti D, Romanelli MN, Cetinkaya-Fisgin A, Arias HR, Hoke A, Gonzalez-Maeso J, Damaj MI.ACS Chem Neurosci · MED 42065994 · DOI 10.1021/acschemneuro.5c01002
• Accelerated recovery using magnesium ibogaine: characterizing the subjective experience of its rapid healing from neuropsychiatric disorders.2026 · Olash C, Buchanan DM, Brown R, Faerman A, Cherian K, Lin G, Spiegel D, Gross JJ, Williams N.Npj Ment Health Res · MED 41620509 · DOI 10.1038/s44184-026-00185-7
• Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows.2025 · Vinarcsik L, Smoller C, Grossberg G.Drugs Aging · MED 40553322 · DOI 10.1007/s40266-025-01221-5
• Total alkaloids of Bulbus Fritillariae Pallidiflorae alleviated silica induced pulmonary inflammation and fibrosis via regulating EMT and TGF-β1/Smad signaling pathway.2025 · Wang D, Zhang F, Tse WM, Tse KWG, Cuomu M, Ye B.Ecotoxicol Environ Saf · MED 41197275 · DOI 10.1016/j.ecoenv.2025.119320
• The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies.2025 · Weleff J, Pulido-Saavedra A, Aghaei AM, Ing K, Arakelian M, Fontenele R, Nero N, Barnett BS, Anand A, Bassir Nia A, Angarita GA.Psychiatry Res · MED 40147088 · DOI 10.1016/j.psychres.2025.116446
• The psychoplastogen tabernanthalog induces neuroplasticity without proximate immediate early gene activation.2025 · Aarrestad IK, Cameron LP, Fenton EM, Casey AB, Rijsketic DR, Patel SD, Sambyal R, Johnson SB, Ly C, Viswanathan J, Barragan EV, Lozano SA, Seban N, Hu H, Powell NA, Chytil M, Meyer R, Rose D, Hempel C, Olson E, Hansen HD, Madsen CA, Knudsen GM, Redd C, Wheeler DG, Guanzon N, Muir J, Hennessey JJ, Quon G, McCorvy JD, Gandhi SP, Rasmussen K, Liston C, Gray JA, Heifets BD, Nord AS, Kim CK, Olson DE.Nat Neurosci · MED 40760185 · DOI 10.1038/s41593-025-02021-1
• The psychoactive compound ibogaine sex-dependently alters the firing rate and afterhyperpolarization of I<sub>h</sub>-negative neurons in the mouse ventral tegmental area.2025 · Eliasen JN, Rezagholizadeh A, Jacobsen HP, Kristiansen U, Kohlmeier KA.Neuroscience · MED 41057132 · DOI 10.1016/j.neuroscience.2025.10.001
• The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials.2025 · Hogea L, Tabugan DC, Costea I, Albai O, Nussbaum L, Cojocaru A, Corsaro L, Anghel T.Medicina (Kaunas) · MED 40005395 · DOI 10.3390/medicina61020278
• The Ibogaine Experience Scale (IES): Development and psychometric properties of a multidimensional measure of ibogaine's subjective effects.2025 · González Espejito F, Esteban Rodríguez L, Pedrero Pérez EJ, Dickinson J, Kohek M, Guimaraes Dos Santos R, Hallak J, Alcázar-Córcoles MÁ, Morgan BL, Bouso JC.PLoS One · MED 41082525 · DOI 10.1371/journal.pone.0333296
• Tabernanthalog, a Non-Hallucinogenic Psychedelic, Alleviates Cancer-Induced Cognitive Deficits via Serotonergic Pathways.2025 · Arinaga M, Yamada J, Maeda S, Okamura A, Oshima Y, Zhang L, Han Y, Iinuma KM, Jinno S.Int J Mol Sci · MED 40806652 · DOI 10.3390/ijms26157519
• Regiospecific hydroxylase and O-methyltransferase for the biosynthesis of anticancer alkaloids in Tabernaemontana elegans (toad tree).2025 · Mann SGA, Richardson MB, Young RN, Deslongchamps G, Qu Y.Plant Physiol Biochem · MED 40554325 · DOI 10.1016/j.plaphy.2025.110161
• Psychedelic-induced behavioral and developmental effects on zebrafish: a systematic review.2025 · de Oliveira AL, de Oliveira DP, Dos Santos RG, Hallak JEC.Prog Neuropsychopharmacol Biol Psychiatry · MED 41125218 · DOI 10.1016/j.pnpbp.2025.111534
• Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.2025 · Piper T, Small F, Brown S, Kelleher M, Mitcheson L, Rucker J, Young AH, Marsden J.Addiction · MED 39887551 · DOI 10.1111/add.16762
• Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders.2025 · Mehtani NJ, Mian MN, Agin-Liebes G, Coker AR, Huebner C, Anderson BT, Mitchell JM.J Psychoactive Drugs · MED 41214462 · DOI 10.1080/02791072.2025.2583960
• Potential Serotonin 5-HT2A Receptor Agonist of Psychoactive Components of <i>Silene undulata</i> Aiton: LC-MS/MS, ADMET, and Molecular Docking Studies.2025 · Alhawarri MB, Olimat S.Curr Pharm Biotechnol · MED 38561607 · DOI 10.2174/0113892010299804240324140017
• Pharmacological Evaluation of Tropane Analogues at the Serotonin Transporter.2025 · Avanes AA, Warren HT, Senthil A, Olson DE.ACS Chem Neurosci · MED 40802711 · DOI 10.1021/acschemneuro.5c00443
• Oxidative Rearrangements of the Alkaloid Intermediate Geissoschizine.2025 · Kamileen MO, Hong B, Gase K, Kunert M, Caputi L, Lichman BR, O'Connor SE.Angew Chem Int Ed Engl · MED 40202182 · DOI 10.1002/anie.202501323
• Old Dog, New Tricks: Ibogaine and Its Analogs as Potential Neurotherapeutics.2025 · Ali S, Tian X, Cunningham KA, Zhou J.J Med Chem · MED 40994282 · DOI 10.1021/acs.jmedchem.5c02510
• Not Losing Momentum: Cross-Sectional Insights into Ibogaine Clinical Trials.2025 · Swieczkowski D, Kwaśny A, Sadko K, Cubała WJ.J Psychoactive Drugs · MED 40251723 · DOI 10.1080/02791072.2025.2491385
• Noribogaine altered intrinsic properties of thalamocortical neurons in a sex-dependent manner.2025 · Villalba S, Bosch S, Di Constanzo L, González B, Torterolo P, Carrera I, Urbano FJ, Bisagno V.Prog Neuropsychopharmacol Biol Psychiatry · MED 40789467 · DOI 10.1016/j.pnpbp.2025.111467
• Modification of natural tryptamines for the treatment of neuropsychiatric diseases.2025 · Palfreyman MG, Varty GB, Stang E, Boltaev U, Avery K, Nivorozhkin A.J Psychopharmacol · MED 41045211 · DOI 10.1177/02698811251368362
• KOR agonists for the treatment and/or prevention of opioid use disorder and cocaine use disorder.2025 · Liu-Chen LY, Huang P.Pharmacol Biochem Behav · MED 40588011 · DOI 10.1016/j.pbb.2025.174056
• Is ibogaine treatment durable? 12-month follow-up of magnesium–ibogaine therapy (MISTIC) in Special Operations Veterans with traumatic brain injuries2025 · Rolle C, Williams N, Faerman A, Lissemore J, Geoly A, Cherian K, Sridhar M, Kim B, Coetzee J, Anker L, Shamma A, Keynan NJ, Brown R, Phillips A, Jester A, Bassano N, Espil F, Kratter I.Support non renseigné dans l’index · PPR PPR1135192 · DOI 10.21203/rs.3.rs-6909189/v1
• Insecticidal activity of a Tabernaemontana arborea root bark alkaloid extract against Culex quinquefasciatus larvae2025 · Krengel F, Pavela R, Carrillo-Bolea A, Dickinson J, Guevara Fefer P.Industrial crops and products. · AGR IND608796578
• Ibogalogs improve spatial and recognition memory in rodents through a mechanism involving 5-HT&lt;sub&gt;2A&lt;/sub&gt; receptor activation-enhanced NMDA receptor activity in hippocampal pyramidal CA1 neurons.2025 · Chagraoui A, Haro Santillan LA, Bocian R, Cohen SJ, Sarmiento Ruíz YE, Knox M, Kazmierska-Grebowska P, Zimoń W, Stackman RW, Flores-Hernandez J, Arias HR.Biomed Pharmacother · MED 41223759 · DOI 10.1016/j.biopha.2025.118742
• Ibogalogs decrease neuropathic pain in mice through a mechanism involving crosstalk between 5-HT&lt;sub&gt;2A&lt;/sub&gt; and mGlu&lt;sub&gt;2&lt;/sub&gt; receptors.2025 · Arias HR, Micheli L, Jensen AA, Galant S, Vandermoere F, Venturi D, Manetti D, Romanelli MN, Ghelardini C, Marin P, Di Cesare Mannelli L.Biomed Pharmacother · MED 39938347 · DOI 10.1016/j.biopha.2025.117887
• Ibogaine: Revisiting an Ancient Alkaloid for Modern Opioid Dependence.2025 · Moore MD, Moore RK, Alzghari SK.Subst Use Misuse · MED 41404929 · DOI 10.1080/10826084.2025.2604213
• Ibogaine's potential role in supporting reward system recovery across diagnostic boundaries.2025 · Nicolas M.Front Pharmacol · MED 41424776 · DOI 10.3389/fphar.2025.1744383
• Ibogaine induces juvenile-like plasticity and modulates functional and structural regulators of plasticity in the adult mouse visual cortex2025 · Acuña A, Billeri F, Totaro V, Carrera I, Mesa JM, Pizzorusso T, Rossi FM.Support non renseigné dans l’index · PPR PPR1135742 · DOI 10.21203/rs.3.rs-8387313/v1
• Harnessing Pharmacogenomics in Clinical Research on Psychedelic-Assisted Therapy.2025 · Halman A, Conyers R, Moore C, Khatri D, Sarris J, Perkins D.Clin Pharmacol Ther · MED 39345195 · DOI 10.1002/cpt.3459
• Electrophysiological Methods to Explore the Function of Monoamine Transporters.2025 · Boytsov D, Freissmuth M, Sandtner W.Adv Neurobiol · MED 41051709 · DOI 10.1007/978-3-031-96364-3_6
• Efficient and modular synthesis of ibogaine and related alkaloids.2025 · Iyer RN, Favela D, Domokos A, Zhang G, Avanes AA, Carter SJ, Basargin AG, Davis AR, Tantillo DJ, Olson DE.Nat Chem · MED 39915657 · DOI 10.1038/s41557-024-01714-7
• Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies.2025 · Pulido-Saavedra A, Oliva HNP, Prudente TP, Kitaneh R, Nunes EJ, Fogg C, Funaro MC, Weleff J, Nia AB, Angarita GA.Cell Mol Life Sci · MED 39833376 · DOI 10.1007/s00018-024-05519-2
• Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies2025 · Pulido-Saavedra A, Oliva HNP, Prudente TP, Kitaneh R, Nunes EJ, Fogg C, Funaro MC, Weleff J, Nia AB, Angarita GA.Cell. Mol. Life Sci · AGR IND608974685
• Effects of nectar and sugar on the longevity of the mosquito Anopheles gambiae s.l2025 · Khadidiatou CN, koella JC, Guibéhi BK.Support non renseigné dans l’index · PPR PPR1091686 · DOI 10.21203/rs.3.rs-7367548/v1
• Effects of nectar and sugar on the longevity of the mosquito <i>Anopheles gambiae</i> s.l.2025 · Cissé-Niambélé K, Koella JC, Koudou Guibéhi B.Support non renseigné dans l’index · PPR PPR986652 · DOI 10.1101/2025.03.02.641044
• Dimethyltryptamine (DMT) and ibogaine elicit membrane effects in HEK cells transiently transfected with the human 5-HT2A receptor.2025 · Eliasen JN, Kristiansen U, Kohlmeier KA.Brain Res · MED 39732157 · DOI 10.1016/j.brainres.2024.149425
• Development of Bioisosteric <i>Iboga</i> -alkaloids as Antinociceptive and Anxiolytic Agents with Neuroprotective Effects2025 · Gupta A, Bhattacharya T, Pratihar S, Parvage S, Sharma SN, Sarkar A, De A, Karmakar S, Dey S, Sinha S.Support non renseigné dans l’index · PPR PPR983941 · DOI 10.1101/2025.02.24.639821
• Deciphering Ibogaine’s Matrix Pharmacology: Multiple Transporter Modulation at Serotonin Synapses2025 · Hwu C, Havel V, Westergaard X, Mendieta AM, Serrano IC, Hwu J, Walther D, Lankri D, Selinger TL, He K, Liu R, Shern TP, Sun S, Ma B, González B, Goodman HJ, Sonders MS, Baumann MH, Carrera I, Sulzer D, Sames D.Support non renseigné dans l’index · PPR PPR987687 · DOI 10.1101/2025.03.04.641351
• Conserved early steps of stemmadenine biosynthesis2025 · Kamileen MO, Nakamura Y, Sigmund M, Keshan R, Gabe V, Heinicke S, Kunert M, Hong B, Alam R, Kang G, Caputi L, O’Connor SE.Support non renseigné dans l’index · PPR PPR1125848 · DOI 10.1101/2025.11.23.690000
• Characterization of a novel mouse model of Dopamine Transporter Deficiency Syndrome and pharmacological therapeutic strategies2025 · Russo EE, Rezayof A, Wallace C, Williams EQ, Beerepoot P, Milenkovic M, Novalen M, Blundell A, Lipina TV, Locke J, Christian R, Finnie PS, Edgar LJ, Tyndale RF, Watkins-Chow D, Ramsey AJ, Jones SR, Salahpour A.Support non renseigné dans l’index · PPR PPR994583 · DOI 10.1101/2025.03.21.644417
• Changing your mind: neuroplastic mechanisms underlying the therapeutic effect of psychedelics in depression, PTSD, and addiction.2025 · Palhas M, Corne R, Mongeau R.Prog Neuropsychopharmacol Biol Psychiatry · MED 41130352 · DOI 10.1016/j.pnpbp.2025.111533
• Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.2025 · Chen DQ, Inzunza Domínguez JA, Valle Uzeta JM, Pushparaj AP, Dickinson JE.Front Immunol · MED 39981248 · DOI 10.3389/fimmu.2025.1535782
• A case series of ibogaine toxicity reported to the United Kingdom National Poisons Information Service (NPIS) over a 10-year period.2025 · Edwards EP, Gray LA, Elamin MEMO, Veiraiah A, Thanacoody RHK, Coulson JM.Clin Toxicol (Phila) · MED 39882933 · DOI 10.1080/15563650.2024.2447500
• A Thematic Analysis of the Subjective Effects and Phenomenology of Ibogaine Administered in a Clinical Setting2025 · Torre JL, Cheung SM, Kam A, Sackett NB.Support non renseigné dans l’index · PPR PPR1114579 · DOI 10.21203/rs.3.rs-8022144/v1
• A Systematic Review and Meta-Analysis Investigating the Efficacy of Various Psychedelic Drugs for the Treatment of Substance Use Disorder.2025 · Keighley EE, Abo Hamza E, Bedewy DA, Nalla S, Moustafa AA.Healthcare (Basel) · MED 41228035 · DOI 10.3390/healthcare13212668
• A Comprehensive Meta-Analysis Investigating the Efficacy of Various Psychedelic Drugs for the Treatment of Substance Misuse2025 · Keighley EE, Bedewy D, Hamza EA, Nalla S, Moustafa A.Support non renseigné dans l’index · PPR PPR1012895 · DOI 10.31234/osf.io/mjhwf_v1
• What is needed for the roll-out of psychedelic treatments?2024 · Xenakis SN, Shannon SM.Curr Opin Psychiatry · MED 38726805 · DOI 10.1097/yco.0000000000000946
• Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions.2024 · Modlin NL, Creed M, Sarang M, Maggio C, Rucker JJ, Williamson V.Neuropsychiatr Dis Treat · MED 38268571 · DOI 10.2147/ndt.s432537
• Three Decades of Research on the Development of Ibogaine Treatment of Substance Use Disorders: A Scientometric Analysis.2024 · Fernandes-Nascimento MH, Negrão AB, Viana-Ferreira K, Chaves BDR, Wang YP.J Psychoactive Drugs · MED 37927218 · DOI 10.1080/02791072.2023.2276230
• Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.2024 · Valdez T, Patel V, Senesombath N, Hatahet-Donovan Z, Hornick M.Pharmaceuticals (Basel) · MED 39598395 · DOI 10.3390/ph17111484
• Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders2024 · Valdez T, Patel V, Senesombath D, Hatahet-Donovan Z, Hornick MG.Support non renseigné dans l’index · PPR PPR926532 · DOI 10.20944/preprints202410.1406.v1
• The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.2024 · Wilkes R, Roberts DM, Liknaitzky P, Brett J.Clin Toxicol (Phila) · MED 38753585 · DOI 10.1080/15563650.2024.2346612
• The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.2024 · Knuijver T, Ter Heine R, Schellekens AFA, Heydari P, Lucas L, Westra S, Belgers M, van Oosteren T, Verkes RJ, Kramers C.J Psychopharmacol · MED 38519421 · DOI 10.1177/02698811241237873
• The Nonclassic Psychedelic Ibogaine Disrupts Cognitive Maps.2024 · Ivan VE, Tomàs-Cuesta DP, Esteves IM, Curic D, Mohajerani M, McNaughton BL, Davidsen J, Gruber AJ.Biol Psychiatry Glob Open Sci · MED 38298796 · DOI 10.1016/j.bpsgos.2023.07.008
• The Global Psychedelic Survey: Consumer characteristics, patterns of use, and access in primarily anglophone regions around the world.2024 · Lake S, Lucas P.Int J Drug Policy · MED 38936219 · DOI 10.1016/j.drugpo.2024.104507
• Tabernanthalog and ibogainalog inhibit the α7 and α9α10 nicotinic acetylcholine receptors via different mechanisms and with higher potency than the GABA&lt;sub&gt;A&lt;/sub&gt; receptor and Ca&lt;sub&gt;V&lt;/sub&gt;2.2 channel.2024 · Tae HS, Ortells MO, Yousuf A, Xu SQ, Akk G, Adams DJ, Arias HR.Biochem Pharmacol · MED 38580167 · DOI 10.1016/j.bcp.2024.116183
• Streamlined screening platforms lead to the discovery of pachysiphine synthase from Tabernanthe iboga.2024 · Kamileen MO, Nakamura Y, Luck K, Heinicke S, Hong B, Colinas M, Lichman BR, O'Connor SE.New Phytol · MED 39285533 · DOI 10.1111/nph.20133
• Streamlined screening platforms lead to the discovery of pachysiphine synthase from <i>Tabernanthe iboga</i>2024 · Kamileen MO, Nakamura Y, Luck K, Heinicke S, Hong B, Colinas M, Lichman BR, O’Connor SE.Support non renseigné dans l’index · PPR PPR875619 · DOI 10.1101/2024.06.30.601415
• Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study.2024 · Borkel LF, Rojas-Hernández J, Henríquez-Hernández LA, Santana Del Pino Á, Quintana-Hernández DJ.Expert Rev Clin Pharmacol · MED 38108102 · DOI 10.1080/17512433.2023.2295997
• Psychoactive plant derivatives (ayahuasca, ibogaine, kratom) and their application in opioid withdrawal and use disorder - a narrative review.2024 · Arenson A, Campbell CI, Remler I.J Addict Dis · MED 37199191 · DOI 10.1080/10550887.2023.2195777
• Psychedelics: From Cave Art to 21st-Century Medicine for Addiction.2024 · Vamvakopoulou IA, Nutt DJ.Eur Addict Res · MED 39321788 · DOI 10.1159/000540062
• Psychedelic Therapy: A Primer for Primary Care Clinicians-Ibogaine.2024 · Cherian K, Shinozuka K, Tabaac BJ, Arenas A, Beutler BD, Evans VD, Fasano C, Muir OS.Am J Ther · MED 38518270 · DOI 10.1097/mjt.0000000000001723
• Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.2024 · Tabaac BJ, Shinozuka K, Arenas A, Beutler BD, Cherian K, Evans VD, Fasano C, Muir OS.Am J Ther · MED 38518266 · DOI 10.1097/mjt.0000000000001727
• Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans.2024 · Armstrong SB, Xin Y, Sepeda ND, Polanco M, Averill LA, Davis AK.Mil Psychol · MED 38377244 · DOI 10.1080/08995605.2022.2156200
• Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models.2024 · Havel V, Kruegel AC, Bechand B, McIntosh S, Stallings L, Hodges A, Wulf MG, Nelson M, Hunkele A, Ansonoff M, Pintar JE, Hwu C, Ople RS, Abi-Gerges N, Zaidi SA, Katritch V, Yang M, Javitch JA, Majumdar S, Hemby SE, Sames D.Nat Commun · MED 39304653 · DOI 10.1038/s41467-024-51856-y
• On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders.2024 · Hoyer D.Support non renseigné dans l’index · PPR PPR857433 · DOI 10.22541/au.171648613.31141136/v1
• Noribogaine acute administration in rats promotes wakefulness and suppresses REM sleep.2024 · Castro-Nin JP, Serantes D, Rodriguez P, Gonzalez B, Carrera I, Torterolo P, González J.Psychopharmacology (Berl) · MED 38467891 · DOI 10.1007/s00213-024-06572-2
• Non-hallucinogenic compounds derived from iboga alkaloids alleviate neuropathic and visceral pain in mice through a mechanism involving 5-HT_2A receptor activation.2024 · Arias HR, Micheli L, Rudin D, Bento O, Borsdorf S, Ciampi C, Marin P, Ponimaskin E, Manetti D, Romanelli MN, Ghelardini C, Liechti ME, Di Cesare Mannelli L.Biomed Pharmacother · MED 38889634 · DOI 10.1016/j.biopha.2024.116867
• New frontiers in the biosynthesis of psychoactive specialized metabolites.2024 · Li G, Facchini PJ.Curr Opin Plant Biol · MED 39288539 · DOI 10.1016/j.pbi.2024.102626
• New Approach Methodologies (NAMs) for ad hoc human health risk assessment of food and non-food products - Proceedings of a workshop.2024 · de Wit L, Hendriks H, van Engelen J, Heusinkveld H, Kienhuis A, Rorije E, Woutersen M, van der Zee M, Jeurissen S.Regul Toxicol Pharmacol · MED 38555098 · DOI 10.1016/j.yrtph.2024.105615
• Multiple Episodes of Cardiac Arrest Induced by Treatment With Ibogaine: A Case Report.2024 · Mestre D, Paula A, Gil FP, Vaz J.Cureus · MED 39081435 · DOI 10.7759/cureus.63487
• Magnesium-ibogaine therapy in veterans with traumatic brain injuries.2024 · Cherian KN, Keynan JN, Anker L, Faerman A, Brown RE, Shamma A, Keynan O, Coetzee JP, Batail JM, Phillips A, Bassano NJ, Sahlem GL, Inzunza J, Millar T, Dickinson J, Rolle CE, Keller J, Adamson M, Kratter IH, Williams NR.Nat Med · MED 38182784 · DOI 10.1038/s41591-023-02705-w
• Ibogaine therapy in TBI.2024 · Welberg L.Nat Neurosci · MED 38326431 · DOI 10.1038/s41593-024-01582-x
• Ibogaine administration following repeated morphine administration upregulates myelination markers 2', 3'-cyclic nucleotide 3'-phosphodiesterase (CNP) and myelin basic protein (MBP) mRNA and protein expression in the internal capsule of Sprague Dawley rats.2024 · Govender D, Moloko L, Papathanasopoulos M, Tumba N, Owen G, Calvey T.Front Neurosci · MED 39114487 · DOI 10.3389/fnins.2024.1378841
• Ibogaine Induces Cardiotoxic Necrosis in Rats—The Role of Redox Processes2024 · Vidonja Uzelac T, Tatalović N, Mijović M, Miler M, Grahovac T, Oreščanin Dušić Z, Nikolić-Kokić A, Blagojević D.Int J Mol Sci · PMC PMC11203496
• Ibogaine Induces Cardiotoxic Necrosis in Rats-The Role of Redox Processes.2024 · Vidonja Uzelac T, Tatalović N, Mijović M, Miler M, Grahovac T, Oreščanin Dušić Z, Nikolić-Kokić A, Blagojević D.Int J Mol Sci · MED 38928231 · DOI 10.3390/ijms25126527
• Evolution and diversification of carboxylesterase-like [4+2] cyclases in aspidosperma and iboga alkaloid biosynthesis.2024 · DeMars MD, O'Connor SE.Proc Natl Acad Sci U S A · MED 38319969 · DOI 10.1073/pnas.2318586121
• Divergent biosynthesis of monoterpene indole alkaloids from geissoschizine2024 · Kamileen MO, Hong B, Gase K, Kunert M, Caputi L, Lichman BR, O’Connor SE.Support non renseigné dans l’index · PPR PPR930683 · DOI 10.1101/2024.10.22.619577
• Disrupting Substance Use Disorder: The Chemistry of Iboga Alkaloids.2024 · Hughes AJ, Hamelink CR, Townsend SD.European J Org Chem · MED 40895173 · DOI 10.1002/ejoc.202400432
• Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.2024 · Gomez-Escolar A, Folch-Sanchez D, Stefaniuk J, Swithenbank Z, Nisa A, Braddick F, Idrees Chaudhary N, van der Meer PB, Batalla A.CNS Drugs · MED 39033264 · DOI 10.1007/s40263-024-01101-3
• Coronaridine congeners induce anticonvulsant activity in rodents by hippocampal mechanisms involving mainly potentiation of GABA_A receptors.2024 · Arias HR, Kazmierska-Grebowska P, Kowalczyk T, Shim Y, Caban B, Aman C, Allain AE, De Deurwaerdère P, Chagraoui A.Eur J Pharmacol · MED 39179091 · DOI 10.1016/j.ejphar.2024.176911
• Catharanthine Modulates Mesolimbic Dopamine Transmission and Nicotine Psychomotor Effects via Inhibition of α6-Nicotinic Receptors and Dopamine Transporters.2024 · Williams BM, Steed ND, Woolley JT, Moedl AA, Nelson CA, Jones GC, Burris MD, Arias HR, Kim OH, Jang EY, Hone AJ, McIntosh JM, Yorgason JT, Steffensen SC.ACS Chem Neurosci · MED 38613458 · DOI 10.1021/acschemneuro.3c00478
• Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders.2024 · Wong S, Yu AY, Fabiano N, Finkelstein O, Pasricha A, Jones BDM, Rosenblat JD, Blumberger DM, Mulsant BH, Husain MI.J Psychoactive Drugs · MED 37615379 · DOI 10.1080/02791072.2023.2251133
• Analysis and characteristics of coronaridine, an alkaloid found in &lt;i&gt;Catharanthus roseus&lt;/i&gt;.2024 · Kisaka H, Karakawa S, Miwa T, Hirano H, Onuki T, Iyo M.Plant Biotechnol (Tokyo) · MED 40083579 · DOI 10.5511/plantbiotechnology.24.0717a
• Allosteric Inhibition and Pharmacochaperoning of the Serotonin Transporter by the Antidepressant Drugs Trazodone and Nefazodone.2024 · El-Kasaby A, Boytsov D, Kasture A, Krumpl G, Hummel T, Freissmuth M, Sandtner W.Mol Pharmacol · MED 38769018 · DOI 10.1124/molpharm.124.000881
• A transcriptomic analysis in mice following a single dose of ibogaine identifies new potential therapeutic targets.2024 · Biosca-Brull J, Ona G, Alarcón-Franco L, Colomina MT.Transl Psychiatry · MED 38242896 · DOI 10.1038/s41398-024-02773-7
• A survey investigating United States federal grant submissions proposing to investigate therapeutic applications of psychedelics2024 · Barnett BS.Support non renseigné dans l’index · PPR PPR923451 · DOI 10.1101/2024.10.12.24315367
• 5-HT_2A Receptor Knockout Mice Show Sex-Dependent Differences following Acute Noribogaine Administration.2024 · Villalba S, González B, Junge S, Bernardi A, González J, Fagúndez C, Torterolo P, Carrera I, Urbano FJ, Bisagno V.Int J Mol Sci · MED 38255760 · DOI 10.3390/ijms25020687
• What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders.2023 · Straub CJ, Rusali LE, Kremiller KM, Riley AP.J Med Chem · MED 36440853 · DOI 10.1021/acs.jmedchem.2c01562
• Underground ibogaine use for the treatment of substance use disorders: A qualitative analysis of subjective experiences.2023 · Rodríguez-Cano BJ, Kohek M, Ona G, Alcázar-Córcoles MÁ, Dos Santos RG, Hallak JEC, Bouso JC.Drug Alcohol Rev · MED 36456173 · DOI 10.1111/dar.13587
• The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.2023 · Mastinu A, Anyanwu M, Carone M, Abate G, Bonini SA, Peron G, Tirelli E, Pucci M, Ribaudo G, Oselladore E, Premoli M, Gianoncelli A, Uberti DL, Memo M.Int J Mol Sci · MED 36674849 · DOI 10.3390/ijms24021329
• Tabernanthalog Reduces Motivation for Heroin and Alcohol in a Polydrug Use Model.2023 · Heinsbroek JA, Giannotti G, Bonilla J, Olson DE, Peters J.Psychedelic Med (New Rochelle) · MED 37360328 · DOI 10.1089/psymed.2023.0009
• Structure-based discovery of conformationally selective inhibitors of the serotonin transporter.2023 · Singh I, Seth A, Billesbølle CB, Braz J, Rodriguiz RM, Roy K, Bekele B, Craik V, Huang XP, Boytsov D, Pogorelov VM, Lak P, O'Donnell H, Sandtner W, Irwin JJ, Roth BL, Basbaum AI, Wetsel WC, Manglik A, Shoichet BK, Rudnick G.Cell · MED 37137306 · DOI 10.1016/j.cell.2023.04.010
• Reactivity of the Iboga Skeleton: Oxidation Study of Ibogaine and Voacangine.2023 · González B, Veiga N, Hernández G, Seoane G, Carrera I.J Nat Prod · MED 37221656 · DOI 10.1021/acs.jnatprod.3c00189
• Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review.2023 · Sharma R, Batchelor R, Sin J.J Psychoactive Drugs · MED 36933948 · DOI 10.1080/02791072.2023.2190319
• Psychedelic Therapy: A Primer for Primary Care Clinicians – Part V. Ibogaine2023 · Cherian K, Shinozuka K, Tabaac BJ, Arenas A, Beutler BD, Evans VD, Fasano C, Muir OS.Support non renseigné dans l’index · PPR PPR779330 · DOI 10.31234/osf.io/v3f4w
• Psychedelic Therapy: A Primer for Primary Care Clinicians – Part I. Historical Perspective and Overview2023 · Tabaac BJ, Shinozuka K, Arenas A, Beutler BD, Cherian K, Evans VD, Fasano C, Muir OS.Support non renseigné dans l’index · PPR PPR779328 · DOI 10.31234/osf.io/byms6
• Psychedelic Drug Legislative Reform and Legalization in the US.2023 · Siegel JS, Daily JE, Perry DA, Nicol GE.JAMA Psychiatry · MED 36477830 · DOI 10.1001/jamapsychiatry.2022.4101
• Potent Anti-amoebic Effects of Ibogaine, Voacangine and the Root Bark Alkaloid Fraction of Tabernaemontana arborea.2023 · Carrero JC, Curay-Herrera V, Chacón-Niño L, Krengel F, Guzmán-Gutiérrez SL, Silva-Miranda M, González-Ramírez LC, Bobes RJ, Espitia C, Reyes-Chilpa R, Laclette JP.Planta Med · MED 35338475 · DOI 10.1055/a-1809-1157
• Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico.2023 · Davis AK, Xin Y, Sepeda N, Averill LA.Am J Drug Alcohol Abuse · MED 37734158 · DOI 10.1080/00952990.2023.2220874
• Noribogaine effects on wakefulness and sleep2023 · Castro-Nin JP, Serantes D, Rodriguez P, Gonzalez B, Carrera I, Torterolo P, González J.Support non renseigné dans l’index · PPR PPR699019 · DOI 10.1101/2023.07.26.550725
• Neuroimaging in psychedelic drug development: past, present, and future.2023 · Wall MB, Harding R, Zafar R, Rabiner EA, Nutt DJ, Erritzoe D.Mol Psychiatry · MED 37759038 · DOI 10.1038/s41380-023-02271-0
• Natural psychedelics in the treatment of depression; a review focusing on neurotransmitters.2023 · Jahanabadi S, Amiri S, Karkeh-Abadi M, Razmi A.Fitoterapia · MED 37490982 · DOI 10.1016/j.fitote.2023.105620
• Multi-state Model-Based Identification of Cryptic Allosteric Sites on Human Serotonin Transporter.2023 · Tu G, Xu B, Luo D, Liu J, Liu Z, Chen G, Xue W.ACS Chem Neurosci · MED 37067527 · DOI 10.1021/acschemneuro.3c00155
• Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview.2023 · Ona G, Reverte I, Rossi GN, Dos Santos RG, Hallak JE, Colomina MT, Bouso JC.J Psychopharmacol · MED 37937505 · DOI 10.1177/02698811231200882
• Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies.2023 · Rocha JM, Reis JAS, Bouso JC, Hallak JEC, Dos Santos RG.Eur Arch Psychiatry Clin Neurosci · MED 36947216 · DOI 10.1007/s00406-023-01590-1
• Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature.2023 · Mosca A, Chiappini S, Miuli A, Mancusi G, Santovito MC, Di Carlo F, Pettorruso M, Corkery JM, Canessa C, Martinotti G, Di Giannantonio M.Curr Neuropharmacol · MED 36263479 · DOI 10.2174/1570159x21666221017085612
• IUPHAR - invited review - Ibogaine - A legacy within the current renaissance of psychedelic therapy.2023 · Mash DC.Pharmacol Res · MED 36907284 · DOI 10.1016/j.phrs.2022.106620
• Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder.2023 · Hornick MG, Stefanski A.Front Pharmacol · MED 37675046 · DOI 10.3389/fphar.2023.1221719
• Evolution and Diversification of Carboxylesterase-like [4+2] Cyclases in Aspidosperma and Iboga Alkaloid Biosynthesis2023 · DeMars MD, O’Connor SE.Support non renseigné dans l’index · PPR PPR747617 · DOI 10.1101/2023.10.24.563752
• Disruptive mutations in the serotonin transporter associate serotonin dysfunction with treatment-resistant affective disorder2023 · Støier JF, Jørgensen TN, Sparsø T, Rasmussen HB, Kumar V, Newman AH, Blakely RD, Werge T, Gether U, Herborg F.Support non renseigné dans l’index · PPR PPR716255 · DOI 10.1101/2023.08.29.23294386
• Coronaridine congeners induce sedative and anxiolytic-like activity in naïve and stressed/anxious mice by allosteric mechanisms involving increased GABA_A receptor affinity for GABA.2023 · Arias HR, De Deurwaerdère P, Scholze P, Sakamoto S, Hamachi I, Di Giovanni G, Chagraoui A.Eur J Pharmacol · MED 37331683 · DOI 10.1016/j.ejphar.2023.175854
• Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review.2023 · Zhornitsky S, Oliva HNP, Jayne LA, Allsop ASA, Kaye AP, Potenza MN, Angarita GA.Front Psychiatry · MED 37435405 · DOI 10.3389/fpsyt.2023.1197890
• Changes in functional connectivity preserve scale-free neuronal and behavioral dynamics.2023 · Rabus A, Curic D, Ivan VE, Esteves IM, Gruber AJ, Davidsen J.Phys Rev E · MED 38115411 · DOI 10.1103/physreve.108.l052301
• Changes in functional connectivity preserve scale-free neuronal and behavioral dynamics2023 · Rabus A, Curic D, Ivan VE, Esteves IM, Gruber AJ, Davidsen J.Support non renseigné dans l’index · PPR PPR723942 · DOI 10.1101/2023.09.13.557619
• Central nervous system activity of a Tabernaemontana arborea alkaloid extract involves serotonergic and opioidergic neurotransmission in murine models.2023 · González-Trujano ME, Páez-Martínez N, Krengel F, Martínez-Vargas D, León-Santiago M, Cruz-López B, Puentes-Guerrero JM, Díaz-Cantón JK, Reyes-Chilpa R, Guzmán-Gutiérrez SL.Fitoterapia · MED 37423501 · DOI 10.1016/j.fitote.2023.105602
• Case report: Ibogaine reduced severe neuropathic pain associated with a case of brachial plexus nerve root avulsion.2023 · Dickinson JE, Inzunza JAD, Perez-Villa L, Millar TG, Pushparaj AP.Front Pain Res (Lausanne) · MED 37720911 · DOI 10.3389/fpain.2023.1256396
• Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies.2023 · Weleff J, Akiki TJ, Barnett BS.J Psychoactive Drugs · MED 36218281 · DOI 10.1080/02791072.2022.2133757
• Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.2023 · Forstmann M, Kettner HS, Sagioglou C, Irvine A, Gandy S, Carhart-Harris RL, Luke D.J Psychopharmacol · MED 36601974 · DOI 10.1177/02698811221146356
• A mechanism of uncompetitive inhibition of the serotonin transporter.2023 · Bhat S, El-Kasaby A, Kasture A, Boytsov D, Reichelt JB, Hummel T, Sucic S, Pifl C, Freissmuth M, Sandtner W.Elife · MED 36648438 · DOI 10.7554/elife.82641
• (+)-Catharanthine and (-)-18-methoxycoronaridine induce antidepressant-like activity in mice by differently recruiting serotonergic and norepinephrinergic neurotransmission.2023 · Arias HR, De Deurwaerdère P, El-Kasaby A, Di Giovanni G, Eom S, Lee JH, Freissmuth M, Chagraoui A.Eur J Pharmacol · MED 36549498 · DOI 10.1016/j.ejphar.2022.175454
• United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.2022 · Barnett BS, Parker SE, Weleff J.Int J Drug Policy · MED 34624734 · DOI 10.1016/j.drugpo.2021.103473
• Three-decade research development of ibogaine use for the treatment of substance-related disorders: a bibliometric analysis2022 · Fernandes-Nascimento MH, Negrão AB, Ferreira-Viana k, Chaves BR, Yuan-Pang W.Support non renseigné dans l’index · PPR PPR541579 · DOI 10.21203/rs.3.rs-2031631/v1
• Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders.2022 · Vorobyeva N, Kozlova AA.Front Pharmacol · MED 35837277 · DOI 10.3389/fphar.2022.927984
• The substrate import mechanism of the human serotonin transporter.2022 · Chan MC, Selvam B, Young HJ, Procko E, Shukla D.Biophys J · MED 35114149 · DOI 10.1016/j.bpj.2022.01.024
• The potential of psychedelic medicine - A personal account.2022 · Smith DE.J Neurol Sci · MED 34998238 · DOI 10.1016/j.jns.2021.120128
• The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020).2022 · Ona G, Rocha JM, Bouso JC, Hallak JEC, Borràs T, Colomina MT, Dos Santos RG.Psychopharmacology (Berl) · MED 34406452 · DOI 10.1007/s00213-021-05964-y
• Tabernaemontana arborea and ibogaine induce paroxysmal EEG activity in freely moving mice: Involvement of serotonin 5-HT_1A receptors.2022 · González-Trujano ME, Krengel F, Reyes-Chilpa R, Villasana-Salazar B, González-Gómez JD, Santos-Valencia F, Urbina-Trejo E, Martínez A, Martínez-Vargas D.Neurotoxicology · MED 34999156 · DOI 10.1016/j.neuro.2022.01.002
• Structure-based Discovery of Conformationally Selective Inhibitors of the Serotonin Transporter2022 · Singh I, Seth A, Billesbølle CB, Braz J, Rodriguiz RM, Roy K, Bekele B, Craik V, Huang X, Boytsov D, Lak P, O’Donnell H, Sandtner W, Roth BL, Basbaum AI, Wetsel WC, Manglik A, Shoichet BK, Rudnick G.Support non renseigné dans l’index · PPR PPR505553 · DOI 10.1101/2022.06.13.495991
• Structure-Activity Relationships of Dopamine Transporter Pharmacological Chaperones.2022 · Sutton C, Williams EQ, Homsi H, Beerepoot P, Nazari R, Han D, Ramsey AJ, Mash DC, Olson DE, Blough B, Salahpour A.Front Cell Neurosci · MED 35614973 · DOI 10.3389/fncel.2022.832536
• Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study.2022 · Knuijver T, Schellekens A, Belgers M, Donders R, van Oosteren T, Kramers K, Verkes R.Addiction · MED 33620733 · DOI 10.1111/add.15448
• Response to Luz & Mash on cardiac toxicity of ibogaine.2022 · Schellekens A, Kramers K, Knuijver T, Belgers M, Donders R, Verkes RJ.Addiction · MED 34859515 · DOI 10.1111/add.15775
• Reply to Knuijver et al. on the 'Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study'.2022 · Luz M, Mash DC.Addiction · MED 34542215 · DOI 10.1111/add.15694
• Recycling upstream redox enzymes expands the regioselectivity of cycloaddition in pseudo-aspidosperma alkaloid biosynthesis2022 · Kamileen MO, DeMars MD, Hong B, Nakamura Y, Paetz C, Lichman BR, Sonawane PD, Caputi L, O’Connor SE.Support non renseigné dans l’index · PPR PPR544805 · DOI 10.1101/2022.09.13.507834
• Recycling Upstream Redox Enzymes Expands the Regioselectivity of Cycloaddition in Pseudo-Aspidosperma Alkaloid Biosynthesis.2022 · Kamileen MO, DeMars MD, Hong B, Nakamura Y, Paetz C, Lichman BR, Sonawane PD, Caputi L, O'Connor SE.J Am Chem Soc · MED 36240425 · DOI 10.1021/jacs.2c08107
• Neuroimaging in psychedelic drug development: Past, present, and future2022 · Wall M, Harding R, Zafar R, Rabiner EA, Nutt D, Erritzoe D.Support non renseigné dans l’index · PPR PPR512207 · DOI 10.31234/osf.io/xwu4j
• Natural Products for the Treatment of Drug Addiction: Narrative Review.2022 · Raslan MA.Chem Biodivers · MED 36285806 · DOI 10.1002/cbdv.202200702
• Ibogaine microdosing in a patient with bipolar depression: a case report.2022 · Fernandes-Nascimento MH, Viana-Ferreira K, Chaves BDR, Negrão AB, Wang YP.Braz J Psychiatry · MED 35896190 · DOI 10.47626/1516-4446-2021-2359
• Ibogaine and Their Analogs as Therapeutics for Neurological and Psychiatric Disorders.2022 · Kargbo RB.ACS Med Chem Lett · MED 35707155 · DOI 10.1021/acsmedchemlett.2c00214
• Historical Pathways for Opioid Addiction, Withdrawal with Traditional and Alternative Treatment Options with Ketamine, Cannabinoids, and Noribogaine: A Narrative Review.2022 · Edinoff AN, Wu NW, Nix CA, Bonin B, Mouhaffel R, Vining S, Gibson W, Cornett EM, Murnane KS, Kaye AM, Kaye AD.Health Psychol Res · MED 36628122 · DOI 10.52965/001c.38672
• Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites.2022 · F Martins ML, Heydari P, Li W, Martínez-Chávez A, Venekamp N, Lebre MC, Lucas L, Beijnen JH, Schinkel AH.Front Pharmacol · MED 35308219 · DOI 10.3389/fphar.2022.855000
• Antimycobacterial Activity of Alkaloids and Extracts from Tabernaemontana alba and T. arborea.2022 · Guzmán-Gutiérrez SL, Silva-Miranda M, Krengel F, Huerta-Salazar E, León-Santiago M, Díaz-Cantón JK, Espitia Pinzón C, Reyes-Chilpa R.Planta Med · MED 32392600 · DOI 10.1055/a-1157-1732
• A systematic literature review of clinical trials and therapeutic applications of ibogaine.2022 · Köck P, Froelich K, Walter M, Lang U, Dürsteler KM.J Subst Abuse Treat · MED 35012793 · DOI 10.1016/j.jsat.2021.108717
• A mechanism of uncompetitive inhibition of the serotonin transporter2022 · Bhat S, El-Kasaby A, Kasture A, Boytsov D, Reichelt JB, Hummel T, Sucic S, Pifl C, Freissmuth M, Sandtner W.Support non renseigné dans l’index · PPR PPR531891 · DOI 10.1101/2022.08.11.503588
• Tropane-Based Ibogaine Analog Rescues Folding-Deficient Serotonin and Dopamine Transporters.2021 · Bhat S, Guthrie DA, Kasture A, El-Kasaby A, Cao J, Bonifazi A, Ku T, Giancola JB, Hummel T, Freissmuth M, Newman AH.ACS Pharmacol Transl Sci · MED 33860180 · DOI 10.1021/acsptsci.0c00102
• The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs.2021 · Iyer RN, Favela D, Zhang G, Olson DE.Nat Prod Rep · MED 32794540 · DOI 10.1039/d0np00033g
• Registered clinical studies investigating psychedelic drugs for psychiatric disorders.2021 · Siegel AN, Meshkat S, Benitah K, Lipsitz O, Gill H, Lui LMW, Teopiz KM, McIntyre RS, Rosenblat JD.J Psychiatr Res · MED 34048997 · DOI 10.1016/j.jpsychires.2021.05.019
• Rapid synthesis of azepinoindole derivatives from tryptamine sulfonamides and bromoallyl sulfones <i>via</i> an acid-mediated cyclization and rearrangement.2021 · Gurram R, Nanubolu JB, Menon RS.Chem Commun (Camb) · MED 33346280 · DOI 10.1039/d0cc06991d
• Psychoactive Substances of Natural Origin: Toxicological Aspects, Therapeutic Properties and Analysis in Biological Samples.2021 · Gonçalves J, Luís Â, Gallardo E, Duarte AP.Molecules · MED 33807728 · DOI 10.3390/molecules26051397
• Psychedelics: A new era of treatment?2021 · Torres S.Eur Psychiatry · PMC PMC9475866
• Novel Class of Psychedelic Iboga Alkaloids Disrupts Opioid Use2021 · Havel V, Kruegel AC, Bechand B, McIntosh S, Stallings L, Hodges A, Wulf MG, Nelson M, Hunkele A, Ansonoff M, Pintar JE, Hwu C, Abi-Gerges N, Zaidi SA, Katritch V, Yang M, Javitch JA, Majumdar S, Hemby SE, Sames D.Support non renseigné dans l’index · PPR PPR373400 · DOI 10.1101/2021.07.22.453441
• Identification of Effective Anticancer G-Quadruplex-Targeting Chemotypes through the Exploration of a High Diversity Library of Natural Compounds.2021 · Platella C, Ghirga F, Zizza P, Pompili L, Marzano S, Pagano B, Quaglio D, Vergine V, Cammarone S, Botta B, Biroccio A, Mori M, Montesarchio D.Pharmaceutics · MED 34683905 · DOI 10.3390/pharmaceutics13101611
• Ibogaine-Mediated ROS/Antioxidant Elevation in Isolated Rat Uterus Is β-Adrenergic Receptors and K_ATP Channels Mediated.2021 · Tatalović N, Vidonja Uzelac T, Oreščanin Dušić Z, Nikolić-Kokić A, Bresjanac M, Blagojević D.Antioxidants (Basel) · MED 34829663 · DOI 10.3390/antiox10111792
• Ibogaine Has Sex-Specific Plasma Bioavailability, Histopathological and Redox/Antioxidant Effects in Rat Liver and Kidneys: A Study on Females.2021 · Tatalović N, Vidonja Uzelac T, Mijović M, Koželj G, Nikolić-Kokić A, Oreščanin Dušić Z, Bresjanac M, Blagojević D.Life (Basel) · MED 35054409 · DOI 10.3390/life12010016
• Ibogaine Blocks Cue- and Drug-Induced Reinstatement of Conditioned Place Preference to Ethanol in Male Mice.2021 · Henriques GM, Anjos-Santos A, Rodrigues IRS, Nascimento-Rocha V, Reis HS, Libarino-Santos M, Barros-Santos T, Yokoyama TS, Bertagna NB, Favoretto CA, Moraes CRG, Cruz FC, Barbosa PCR, Marinho EAV, Oliveira-Lima AJ, Berro LF.Front Pharmacol · MED 34621171 · DOI 10.3389/fphar.2021.739012
• Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse.2021 · Luz M, Mash DC.Expert Opin Drug Metab Toxicol · MED 34139922 · DOI 10.1080/17425255.2021.1944099
• Engineering Safer Psychedelics for Treating Addiction.2021 · Peters J, Olson DE.Neurosci Insights · MED 34350400 · DOI 10.1177/26331055211033847
• Efficient Access to the Iboga Skeleton: Optimized Procedure to Obtain Voacangine from <i>Voacanga africana</i> Root Bark.2021 · González B, Fagúndez C, Peixoto de Abreu Lima A, Suescun L, Sellanes D, Seoane GA, Carrera I.ACS Omega · MED 34250335 · DOI 10.1021/acsomega.1c00745
• EEG Gamma Band Alterations and REM-like Traits Underpin the Acute Effect of the Atypical Psychedelic Ibogaine in the Rat.2021 · González J, Cavelli M, Castro-Zaballa S, Mondino A, Tort ABL, Rubido N, Carrera I, Torterolo P.ACS Pharmacol Transl Sci · MED 33860181 · DOI 10.1021/acsptsci.0c00164
• Death due to consumption of ibogaine: case report.2021 · Aćimović T, Atanasijević T, Denić K, Lukić V, Popović V, Bogdanović M.Forensic Sci Med Pathol · MED 33433774 · DOI 10.1007/s12024-020-00342-0
• Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies2021 · Weleff J, Akiki TJ, Barnett BS.Support non renseigné dans l’index · PPR PPR423856 · DOI 10.1101/2021.11.22.21266718
• An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress.2021 · Lu J, Tjia M, Mullen B, Cao B, Lukasiewicz K, Shah-Morales S, Weiser S, Cameron LP, Olson DE, Chen L, Zuo Y.Mol Psychiatry · MED 34035476 · DOI 10.1038/s41380-021-01159-1
• A non-hallucinogenic psychedelic analogue with therapeutic potential.2021 · Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, Vargas MV, McCarroll MN, Taylor JC, Myers-Turnbull D, Liu T, Yaghoobi B, Laskowski LJ, Anderson EI, Zhang G, Viswanathan J, Brown BM, Tjia M, Dunlap LE, Rabow ZT, Fiehn O, Wulff H, McCorvy JD, Lein PJ, Kokel D, Ron D, Peters J, Zuo Y, Olson DE.Nature · MED 33299186 · DOI 10.1038/s41586-020-3008-z
• A new approach methodology (NAM) for the prediction of (nor)ibogaine-induced cardiotoxicity in humans.2021 · Shi M, Wesseling S, Bouwmeester H, Rietjens IMCM.ALTEX · MED 34271588 · DOI 10.14573/altex.2103311
• The Substrate Import Mechanism of the Human Serotonin Transporter2020 · Chan M, Selvam B, Young H, Procko E, Shukla D.Support non renseigné dans l’index · PPR PPR149916 · DOI 10.26434/chemrxiv.9922301.v2
• Reduced expression of ethanol sensitization by α3β4 nicotinic acetylcholine receptors in DBA/2J mice.2020 · Miller CN, Kamens HM.Exp Clin Psychopharmacol · MED 31580099 · DOI 10.1037/pha0000324
• Quantitative Evaluation of a Mexican and a Ghanaian Tabernaemontana Species as Alternatives to Voacanga africana for the Production of Antiaddictive Ibogan Type Alkaloids.2020 · Krengel F, Dickinson J, Jenks C, Reyes-Chilpa R.Chem Biodivers · MED 32232967 · DOI 10.1002/cbdv.202000002
• Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies.2020 · Breeksema JJ, Niemeijer AR, Krediet E, Vermetten E, Schoevers RA.CNS Drugs · MED 32803732 · DOI 10.1007/s40263-020-00748-y
• Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans.2020 · Davis AK, Averill LA, Sepeda ND, Barsuglia JP, Amoroso T.Chronic Stress (Thousand Oaks) · MED 32704581 · DOI 10.1177/2470547020939564
• Ibogaine therapy for addiction: Consumer views from online fora.2020 · Barber M, Gardner J, Savic M, Carter A.Int J Drug Policy · MED 32693321 · DOI 10.1016/j.drugpo.2020.102857
• Gamma band alterations and REM-like traits underpin the acute effect of the atypical psychedelic ibogaine2020 · González J, Cavelli M, Castro-Zaballa S, Mondino A, Tort AB, Rubido N, Carrera I, Torterolo P.Support non renseigné dans l’index · PPR PPR181173 · DOI 10.1101/2020.06.25.172304
• Coronaridine congeners potentiate GABA_A receptors and induce sedative activity in mice in a benzodiazepine-insensitive manner.2020 · Arias HR, Do Rego JL, Do Rego JC, Chen Z, Anouar Y, Scholze P, Gonzales EB, Huang R, Chagraoui A.Prog Neuropsychopharmacol Biol Psychiatry · MED 32194202 · DOI 10.1016/j.pnpbp.2020.109930
• Coronaridine congeners decrease neuropathic pain in mice and inhibit α9α10 nicotinic acetylcholine receptors and Ca_V2.2 channels.2020 · Arias HR, Tae HS, Micheli L, Yousuf A, Ghelardini C, Adams DJ, Di Cesare Mannelli L.Neuropharmacology · MED 32540451 · DOI 10.1016/j.neuropharm.2020.108194
• A tropane-based ibogaine analog rescues folding-deficient SERT and DAT2020 · Bhat S, Guthrie DA, Kasture A, El-Kasaby A, Cao J, Bonifazi A, Ku T, Giancola JB, Hummel T, Freissmuth M, Newman AH.Support non renseigné dans l’index · PPR PPR187634 · DOI 10.1101/2020.07.14.202325
• A Single Administration of the Atypical Psychedelic Ibogaine or its Metabolite Noribogaine Induces an Antidepressant-like Effect in Rats2020 · Rodríguez P, Urbanavicius J, Prieto JP, Fabius S, Reyes AL, Havel V, Sames D, Scorza C, Carrera I.Support non renseigné dans l’index · PPR PPR118085 · DOI 10.26434/chemrxiv.12001407.v1
• A Single Administration of the Atypical Psychedelic Ibogaine or Its Metabolite Noribogaine Induces an Antidepressant-Like Effect in Rats.2020 · Rodrı Guez P, Urbanavicius J, Prieto JP, Fabius S, Reyes AL, Havel V, Sames D, Scorza C, Carrera I.ACS Chem Neurosci · MED 32330007 · DOI 10.1021/acschemneuro.0c00152
• [Neurotrophic mechanisms of psychedelic therapy].2019 · Corne R, Mongeau R.Biol Aujourdhui · MED 31829932 · DOI 10.1051/jbio/2019015
• The α3β4 nicotinic acetylcholine receptor antagonist 18-Methoxycoronaridine decreases binge-like ethanol consumption in adult C57BL/6J mice.2019 · Miller CN, Ruggery C, Kamens HM.Alcohol · MED 30496781 · DOI 10.1016/j.alcohol.2018.11.006
• Substrate and inhibitor binding to the serotonin transporter: Insights from computational, crystallographic, and functional studies.2019 · Zeppelin T, Ladefoged LK, Sinning S, Schiøtt B.Neuropharmacology · MED 30807752 · DOI 10.1016/j.neuropharm.2019.02.030
• Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport.2019 · Coleman JA, Yang D, Zhao Z, Wen PC, Yoshioka C, Tajkhorshid E, Gouaux E.Nature · MED 31019304 · DOI 10.1038/s41586-019-1135-1
• Phytochemical characterisation and effects of the native plant Tabernanthe iboga in models of diabetes2019 · Bading-Taika B.Support non renseigné dans l’index · ETH 797432
• Morphing of Ibogaine: A Successful Attempt into the Search for Sigma-2 Receptor Ligands.2019 · Floresta G, Dichiara M, Gentile D, Prezzavento O, Marrazzo A, Rescifina A, Amata E.Int J Mol Sci · MED 30678129 · DOI 10.3390/ijms20030488
• Metabolite Profiling of Anti-Addictive Alkaloids from Four Mexican Tabernaemontana Species and the Entheogenic African Shrub Tabernanthe iboga (Apocynaceae).2019 · Krengel F, Chevalier Q, Dickinson J, Herrera Santoyo J, Reyes Chilpa R.Chem Biodivers · MED 30618175 · DOI 10.1002/cbdv.201800506
• Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder.2019 · Brown TK, Noller GE, Denenberg JO.J Psychoactive Drugs · MED 30967101 · DOI 10.1080/02791072.2019.1598603
• Ibogaine Consumption With Seizure-Like Episodes, QTc-Prolongation, and Captured Cardiac Dysrhythmias.2019 · Grogan J, Gerona R, Snow JW, Kao L.J Emerg Med · MED 31630892 · DOI 10.1016/j.jemermed.2019.06.052
• Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits.2019 · Marton S, González B, Rodríguez-Bottero S, Miquel E, Martínez-Palma L, Pazos M, Prieto JP, Rodríguez P, Sames D, Seoane G, Scorza C, Cassina P, Carrera I.Front Pharmacol · MED 30890941 · DOI 10.3389/fphar.2019.00193
• Hallucinogens and Their Therapeutic Use: A Literature Review.2019 · Begola MJ, Schillerstrom JE.J Psychiatr Pract · MED 31505518 · DOI 10.1097/pra.0000000000000409
• Extraction and Conversion Studies of the Antiaddictive Alkaloids Coronaridine, Ibogamine, Voacangine, and Ibogaine from Two Mexican Tabernaemontana Species (Apocynaceae).2019 · Krengel F, Mijangos MV, Reyes-Lezama M, Reyes-Chilpa R.Chem Biodivers · MED 31095891 · DOI 10.1002/cbdv.201900175
• Conformational dynamics of the human serotonin transporter during substrate and drug binding.2019 · Möller IR, Slivacka M, Nielsen AK, Rasmussen SGF, Gether U, Loland CJ, Rand KD.Nat Commun · MED 30976000 · DOI 10.1038/s41467-019-09675-z
• Biosynthesis of an Anti-Addiction Agent from the Iboga Plant.2019 · Farrow SC, Kamileen MO, Caputi L, Bussey K, Mundy JEA, McAtee RC, Stephenson CRJ, O'Connor SE.J Am Chem Soc · MED 31364847 · DOI 10.1021/jacs.9b05999
• Biosynthesis of an Anti-Addiction Agent from the Iboga Plant2019 · Farrow SC, Kamileen MO, Caputi L, Bussey K, Mundy JEA, McAtee RC, Stephenson CRJ, O’Connor SE.Support non renseigné dans l’index · PPR PPR80294 · DOI 10.1101/647891
• Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.2018 · Brown TK, Alper K.Am J Drug Alcohol Abuse · MED 28541119 · DOI 10.1080/00952990.2017.1320802
• The Effects of Ibogaine on Uterine Smooth Muscle Contractions: Relation to the Activity of Antioxidant Enzymes.2018 · Oreščanin-Dušić Z, Tatalović N, Vidonja-Uzelac T, Nestorov J, Nikolić-Kokić A, Mijušković A, Spasić M, Paškulin R, Bresjanac M, Blagojević D.Oxid Med Cell Longev · MED 29599898 · DOI 10.1155/2018/5969486
• SLC6 Transporter Folding Diseases and Pharmacochaperoning.2018 · Freissmuth M, Stockner T, Sucic S.Handb Exp Pharmacol · MED 29086036 · DOI 10.1007/164_2017_71
• Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.2018 · Schenberg EE.Front Pharmacol · MED 30026698 · DOI 10.3389/fphar.2018.00733
• Phytochemical characterization of <i>Tabernanthe iboga</i> root bark and its effects on dysfunctional metabolism and cognitive performance in high-fat-fed C57BL/6J mice.2018 · Bading-Taika B, Akinyeke T, Magana AA, Choi J, Ouanesisouk M, Torres ERS, Lione LA, Maier CS, Bobe G, Raber J, Miranda CL, Stevens JF.J Food Bioact · MED 30582133 · DOI 10.31665/jfb.2018.3154
• On the relationship between ibogaine and noribogaine.2018 · Yip L, Deng JF.Clin Toxicol (Phila) · MED 28681614 · DOI 10.1080/15563650.2017.1339890
• Nepenthe-Like Indole Alkaloids with Antimicrobial Activity from Ervatamia chinensis.2018 · Yu HF, Qin XJ, Ding CF, Wei X, Yang J, Luo JR, Liu L, Khan A, Zhang LC, Xia CF, Luo XD.Org Lett · MED 29927253 · DOI 10.1021/acs.orglett.8b01675
• Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.2018 · Noller GE, Frampton CM, Yazar-Klosinski B.Am J Drug Alcohol Abuse · MED 28402682 · DOI 10.1080/00952990.2017.1310218
• Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers.2018 · Corkery JM.Prog Brain Res · MED 30471681 · DOI 10.1016/bs.pbr.2018.08.005
• Ibogaine Modifies GDNF, BDNF and NGF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits2018 · Marton S, González B, Rodríguez S, Miquel E, Martínez Palma L, Pazos M, Prieto JP, Rodríguez P, Sames D, Seoane G, Scorza C, Cassina P, Carrera I.Support non renseigné dans l’index · PPR PPR60267 · DOI 10.26434/chemrxiv.7261559.v1
• Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes.2018 · Mash DC, Duque L, Page B, Allen-Ferdinand K.Front Pharmacol · MED 29922156 · DOI 10.3389/fphar.2018.00529
• Ibogaine Acute Administration in Rats Promotes Wakefulness, Long-Lasting REM Sleep Suppression, and a Distinctive Motor Profile.2018 · González J, Prieto JP, Rodríguez P, Cavelli M, Benedetto L, Mondino A, Pazos M, Seoane G, Carrera I, Scorza C, Torterolo P.Front Pharmacol · MED 29755349 · DOI 10.3389/fphar.2018.00374
• Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence.2018 · Knuijver T, Belgers M, Markus W, Verkes RJ, van Oosteren T, Schellekens A.J Clin Psychopharmacol · MED 30300292 · DOI 10.1097/jcp.0000000000000966
• DARK Classics in Chemical Neuroscience: Ibogaine.2018 · Wasko MJ, Witt-Enderby PA, Surratt CK.ACS Chem Neurosci · MED 30216039 · DOI 10.1021/acschemneuro.8b00294
• Cytochrome P450 and <i>O</i>-methyltransferase catalyze the final steps in the biosynthesis of the anti-addictive alkaloid ibogaine from <i>Tabernanthe iboga</i>.2018 · Farrow SC, Kamileen MO, Meades J, Ameyaw B, Xiao Y, O'Connor SE.J Biol Chem · MED 30030374 · DOI 10.1074/jbc.ra118.004060
• Coronaridine congeners modulate mitochondrial α3β4* nicotinic acetylcholine receptors with different potency and through distinct intra-mitochondrial pathways.2018 · Arias HR, Lykhmus O, Uspenska K, Skok M.Neurochem Int · MED 29277577 · DOI 10.1016/j.neuint.2017.12.008
• Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine.2018 · Malcolm BJ, Polanco M, Barsuglia JP.J Psychoactive Drugs · MED 29608409 · DOI 10.1080/02791072.2018.1447175
• Cardiac arrest after ibogaine intoxication.2018 · Steinberg C, Deyell MW.J Arrhythm · MED 30167018 · DOI 10.1002/joa3.12061
• Breaking the cycle of opioid use disorder with Ibogaine.2018 · C Mash D.Am J Drug Alcohol Abuse · MED 29215917 · DOI 10.1080/00952990.2017.1357184
• An overview of anti-diabetic plants used in Gabon: Pharmacology and toxicology.2018 · Bading Taika B, Bouckandou M, Souza A, Bourobou Bourobou HP, MacKenzie LS, Lione L.J Ethnopharmacol · MED 29305175 · DOI 10.1016/j.jep.2017.12.036
• A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.2018 · Barsuglia JP, Polanco M, Palmer R, Malcolm BJ, Kelmendi B, Calvey T.Prog Brain Res · MED 30471678 · DOI 10.1016/bs.pbr.2018.08.002
• A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification.2018 · Davis AK, Renn E, Windham-Herman AM, Polanco M, Barsuglia JP.J Psychoactive Drugs · MED 30020025 · DOI 10.1080/02791072.2018.1487607
• Toxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaine.2017 · Henstra M, Wong L, Chahbouni A, Swart N, Allaart C, Sombogaard F.Clin Toxicol (Phila) · MED 28489458 · DOI 10.1080/15563650.2017.1287372
• The contribution of α4β2 and non-α4β2 nicotinic acetylcholine receptors to the discriminative stimulus effects of nicotine and varenicline in mice.2017 · de Moura FB, McMahon LR.Psychopharmacology (Berl) · MED 28028600 · DOI 10.1007/s00213-016-4514-4
• The Iboga Alkaloids.2017 · Lavaud C, Massiot G.Prog Chem Org Nat Prod · MED 28194562 · DOI 10.1007/978-3-319-49712-9_2
• Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning.2017 · Davis AK, Barsuglia JP, Windham-Herman AM, Lynch M, Polanco M.J Psychedelic Stud · MED 30272050 · DOI 10.1556/2054.01.2017.009
• Selectivity of coronaridine congeners at nicotinic acetylcholine receptors and inhibitory activity on mouse medial habenula.2017 · Arias HR, Jin X, Feuerbach D, Drenan RM.Int J Biochem Cell Biol · MED 29042244 · DOI 10.1016/j.biocel.2017.10.006
• Relax, Cool Down and Scaffold: How to Restore Surface Expression of Folding-Deficient Mutant GPCRs and SLC6 Transporters.2017 · Asjad HMM, Nasrollahi-Shirazi S, Sucic S, Freissmuth M, Nanoff C.Int J Mol Sci · MED 29135937 · DOI 10.3390/ijms18112416
• Pharmacochaperoning in a &lt;i&gt;Drosophila&lt;/i&gt; model system rescues human dopamine transporter variants associated with infantile/juvenile parkinsonism.2017 · Asjad HMM, Kasture A, El-Kasaby A, Sackel M, Hummel T, Freissmuth M, Sucic S.J Biol Chem · MED 28972153 · DOI 10.1074/jbc.m117.797092
• Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences.2017 · Heink A, Katsikas S, Lange-Altman T.J Psychoactive Drugs · MED 28266890 · DOI 10.1080/02791072.2017.1290855
• Anxiolytic-like effects of noribogaine in zebrafish.2017 · Kalueff AV, Kaluyeva A, Maillet EL.Behav Brain Res · MED 28479267 · DOI 10.1016/j.bbr.2017.05.008
• Anti-addiction Drug Ibogaine Prolongs the Action Potential in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.2017 · Rubi L, Eckert D, Boehm S, Hilber K, Koenig X.Cardiovasc Toxicol · MED 27020671 · DOI 10.1007/s12012-016-9366-y
• hERG Blockade by Iboga Alkaloids.2016 · Alper K, Bai R, Liu N, Fowler SJ, Huang XP, Priori SG, Ruan Y.Cardiovasc Toxicol · MED 25636206 · DOI 10.1007/s12012-015-9311-5
• [Ibogaine - structure, influence on human body, clinical relevance].2016 · Zdrojewicz Z, Kuszczak B, Olszak N.Pol Merkur Lekarski · MED 27734823
• When transporters fail to be transported: how to rescue folding-deficient SLC6 transporters.2016 · Sucic S, Kasture A, Mazhar Asjad HM, Kern C, El-Kasaby A, Freissmuth M.J Neurol Neuromedicine · MED 28405636 · DOI 10.29245/2572.942x/2016/9.1098
• Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report.2016 · Cloutier-Gill L, Wood E, Millar T, Ferris C, Eugenia Socias M.J Psychoactive Drugs · MED 27192438 · DOI 10.1080/02791072.2016.1180467
• Quantification of Anti-Addictive Alkaloids Ibogaine and Voacangine in In Vivo- and In Vitro-Grown Plants of Two Mexican Tabernaemontana Species.2016 · Krengel F, Herrera Santoyo J, Olivera Flores TJ, Chávez Ávila VM, Pérez Flores FJ, Reyes Chilpa R.Chem Biodivers · MED 27448833 · DOI 10.1002/cbdv.201600146
• Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells.2016 · Beerepoot P, Lam VM, Salahpour A.J Biol Chem · MED 27555326 · DOI 10.1074/jbc.m116.749119
• Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents.2016 · Mash DC, Ameer B, Prou D, Howes JF, Maillet EL.J Psychopharmacol · MED 27044509 · DOI 10.1177/0269881116641331
• On the toxicity of ibogaine.2016 · Yip L, Deng JF.Clin Toxicol (Phila) · MED 27243473 · DOI 10.1080/15563650.2016.1190017
• In reply - on the toxicity of ibogaine.2016 · Brunt TM, Litjens RP.Clin Toxicol (Phila) · MED 27243280 · DOI 10.1080/15563650.2016.1190018
• Ibogaine-associated cardiac arrest and death: case report and review of the literature.2016 · Meisner JA, Wilcox SR, Richards JB.Ther Adv Psychopharmacol · MED 27141291 · DOI 10.1177/2045125315626073
• Ibogaine for treating drug dependence. What is a safe dose?2016 · Schep LJ, Slaughter RJ, Galea S, Newcombe D.Drug Alcohol Depend · MED 27426011 · DOI 10.1016/j.drugalcdep.2016.07.005
• Ibogaine and addiction in the animal model, a systematic review and meta-analysis.2016 · Belgers M, Leenaars M, Homberg JR, Ritskes-Hoitinga M, Schellekens AF, Hooijmans CR.Transl Psychiatry · MED 27244235 · DOI 10.1038/tp.2016.71
• How toxic is ibogaine?2016 · Litjens RP, Brunt TM.Clin Toxicol (Phila) · MED 26807959 · DOI 10.3109/15563650.2016.1138226
• Functional neurotoxicity evaluation of noribogaine using video-EEG in cynomolgus monkeys.2016 · Authier S, Accardi MV, Paquette D, Pouliot M, Arezzo J, Stubbs RJ, Gerson RJ, Friedhoff LT, Weis H.J Pharmacol Toxicol Methods · MED 27126304 · DOI 10.1016/j.vascn.2016.04.012
• Functional Rescue of a Misfolded &lt;i&gt;Drosophila melanogaster&lt;/i&gt; Dopamine Transporter Mutant Associated with a Sleepless Phenotype by Pharmacological Chaperones.2016 · Kasture A, El-Kasaby A, Szöllősi D, Asjad HMM, Grimm A, Stockner T, Hummel T, Freissmuth M, Sucic S.J Biol Chem · MED 27481941 · DOI 10.1074/jbc.m116.737551
• Effects of low dose ibogaine on subjective mood state and psychological performance.2016 · Forsyth B, Machado L, Jowett T, Jakobi H, Garbe K, Winter H, Glue P.J Ethnopharmacol · MED 27180314 · DOI 10.1016/j.jep.2016.05.022
• Deconstructing the Iboga Alkaloid Skeleton: Potentiation of FGF2-induced Glial Cell Line-Derived Neurotrophic Factor Release by a Novel Compound.2016 · Gassaway MM, Jacques TL, Kruegel AC, Karpowicz RJ, Li X, Li S, Myer Y, Sames D.ACS Chem Biol · MED 26517751 · DOI 10.1021/acschembio.5b00678
• Death related to consumption of Rauvolfia sp. powder mislabeled as Tabernanthe iboga.2016 · Gicquel T, Hugbart C, Le Devehat F, Lepage S, Baert A, Bouvet R, Morel I.Forensic Sci Int · MED 27342343 · DOI 10.1016/j.forsciint.2016.06.014
• Control of serotonin transporter phosphorylation by conformational state.2016 · Zhang YW, Turk BE, Rudnick G.Proc Natl Acad Sci U S A · MED 27140629 · DOI 10.1073/pnas.1603282113
• Bioinspired Collective Syntheses of Iboga-Type Indole Alkaloids.2016 · Zhao G, Xie X, Sun H, Yuan Z, Zhong Z, Tang S, She X.Org Lett · MED 27160167 · DOI 10.1021/acs.orglett.6b00989
• Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients.2016 · Glue P, Cape G, Tunnicliff D, Lockhart M, Lam F, Hung N, Hung CT, Harland S, Devane J, Crockett RS, Howes J, Darpo B, Zhou M, Weis H, Friedhoff L.Clin Pharmacol Drug Dev · MED 27870477 · DOI 10.1002/cpdd.254
• Acute oral 18-methoxycoronaridine (18-MC) decreases both alcohol intake and IV nicotine self-administration in rats.2016 · Rezvani AH, Cauley MC, Slade S, Wells C, Glick S, Rose JE, Levin ED.Pharmacol Biochem Behav · MED 27984095 · DOI 10.1016/j.pbb.2016.10.010
• A Case of QT Prolongation and Torsades de Pointes Caused by Ibogaine Toxicity.2016 · Hildyard C, Macklin P, Prendergast B, Bashir Y.J Emerg Med · MED 26329675 · DOI 10.1016/j.jemermed.2015.06.051
• 18-Methoxycoronaridine acts in the medial habenula to attenuate behavioral and neurochemical sensitization to nicotine.2016 · Eggan BL, McCallum SE.Behav Brain Res · MED 27059333 · DOI 10.1016/j.bbr.2016.04.008
• [Psychedelics and quasi-psychedelics in the light of contemporary research: medical cannabis, MDMA, salvinorin A, ibogaine and ayahuasca].2015 · Szabó A, Kazai A, Frecska E, Brys Z.Neuropsychopharmacol Hung · MED 26485742
• The anti-addiction drug ibogaine and the heart: a delicate relation.2015 · Koenig X, Hilber K.Molecules · MED 25642835 · DOI 10.3390/molecules20022208
• Screening approach by ultra-high performance liquid chromatography-tandem mass spectrometry for the blood quantification of thirty-four toxic principles of plant origin. Application to forensic toxicology.2015 · Carlier J, Guitton J, Romeuf L, Bévalot F, Boyer B, Fanton L, Gaillard Y.J Chromatogr B Analyt Technol Biomed Life Sci · MED 25438245 · DOI 10.1016/j.jchromb.2014.10.028
• Noribogaine reduces nicotine self-administration in rats.2015 · Chang Q, Hanania T, Mash DC, Maillet EL.J Psychopharmacol · MED 25995321 · DOI 10.1177/0269881115584461
• Noribogaine is a G-protein biased κ-opioid receptor agonist.2015 · Maillet EL, Milon N, Heghinian MD, Fishback J, Schürer SC, Garamszegi N, Mash DC.Neuropharmacology · MED 26302653 · DOI 10.1016/j.neuropharm.2015.08.032
• Mania following use of ibogaine: A case series.2015 · Marta CJ, Ryan WC, Kopelowicz A, Koek RJ.Am J Addict · MED 25877487 · DOI 10.1111/ajad.12209
• Internet-purchased ibogaine toxicity confirmed with serum, urine, and product content levels.2015 · O'Connell CW, Gerona RR, Friesen MW, Ly BT.Am J Emerg Med · MED 25687617 · DOI 10.1016/j.ajem.2014.12.023
• Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers.2015 · Glue P, Winter H, Garbe K, Jakobi H, Lyudin A, Lenagh-Glue Z, Hung CT.J Clin Pharmacol · MED 25651476 · DOI 10.1002/jcph.471
• Ex vivo effects of ibogaine on the activity of antioxidative enzymes in human erythrocytes.2015 · Nikolić-Kokić A, Oreščanin-Dušić Z, Spasojević I, Slavić M, Mijušković A, Paškulin R, Miljević Č, Spasić MB, Blagojević DP.J Ethnopharmacol · MED 25660330 · DOI 10.1016/j.jep.2015.01.037
• Coronaridine congeners inhibit human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites.2015 · Arias HR, Targowska-Duda KM, Feuerbach D, Jozwiak K.Int J Biochem Cell Biol · MED 26022277 · DOI 10.1016/j.biocel.2015.05.015
• Can psychedelic compounds play a part in drug dependence therapy?2015 · Sessa B, Johnson MW.Br J Psychiatry · MED 25561484 · DOI 10.1192/bjp.bp.114.148031
• Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability.2015 · Glue P, Lockhart M, Lam F, Hung N, Hung CT, Friedhoff L.J Clin Pharmacol · MED 25279818 · DOI 10.1002/jcph.404
• A salt bridge linking the first intracellular loop with the C terminus facilitates the folding of the serotonin transporter.2015 · Koban F, El-Kasaby A, Häusler C, Stockner T, Simbrunner BM, Sitte HH, Freissmuth M, Sucic S.J Biol Chem · MED 25869136 · DOI 10.1074/jbc.m115.641357
• "Herbal seizures"--atypical symptoms after ibogaine intoxication: a case report.2015 · Breuer L, Kasper BS, Schwarze B, Gschossmann JM, Kornhuber J, Müller HH.J Med Case Rep · MED 26518760 · DOI 10.1186/s13256-015-0731-4
• Treating drug dependence with the aid of ibogaine: a retrospective study.2014 · Schenberg EE, de Castro Comis MA, Chaves BR, da Silveira DX.J Psychopharmacol · MED 25271214 · DOI 10.1177/0269881114552713
• Soma, food of the immortals according to the Bower Manuscript (Kashmir, 6th century A.D.).2014 · Leonti M, Casu L.J Ethnopharmacol · MED 24907429 · DOI 10.1016/j.jep.2014.05.029
• Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca.2014 · Winkelman M.Curr Drug Abuse Rev · MED 25563446 · DOI 10.2174/1874473708666150107120011
• Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine.2014 · Thurner P, Stary-Weinzinger A, Gafar H, Gawali VS, Kudlacek O, Zezula J, Hilber K, Boehm S, Sandtner W, Koenig X.J Pharmacol Exp Ther · MED 24307198 · DOI 10.1124/jpet.113.209643
• Iboga-Type Alkaloids from Ervatamia officinalis.2014 · Tang BQ, Wang WJ, Huang XJ, Li GQ, Wang L, Jiang RW, Yang TT, Shi L, Zhang XQ, Ye WC.J Nat Prod · MED 25093992 · DOI 10.1021/np500240b
• History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS).2014 · Emerson A, Ponté L, Jerome L, Doblin R.J Psychoactive Drugs · MED 24830183 · DOI 10.1080/02791072.2014.877321
• Cardiac arrest after ibogaine ingestion.2014 · Vlaanderen L, Martial LC, Franssen EJ, van der Voort PH, Oosterwerff E, Somsen GA.Clin Toxicol (Phila) · MED 24940646 · DOI 10.3109/15563650.2014.927477
• Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk.2014 · Koenig X, Kovar M, Boehm S, Sandtner W, Hilber K.Addict Biol · MED 22458604 · DOI 10.1111/j.1369-1600.2012.00447.x
• A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 β-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches.2014 · Meyer MR, Caspar A, Brandt SD, Maurer HH.Anal Bioanal Chem · MED 24173660 · DOI 10.1007/s00216-013-7425-9
• A cytosolic relay of heat shock proteins HSP70-1A and HSP90β monitors the folding trajectory of the serotonin transporter.2014 · El-Kasaby A, Koban F, Sitte HH, Freissmuth M, Sucic S.J Biol Chem · MED 25202009 · DOI 10.1074/jbc.m114.595090
• [Emergent drugs (III): hallucinogenic plants and mushrooms].2013 · Burillo-Putze G, López Briz E, Climent Díaz B, Munné Mas P, Nogue Xarau S, Pinillos MA, Hoffman RS.An Sist Sanit Navar · MED 24406363 · DOI 10.4321/s1137-66272013000300015
• Unique and potent effects of acute ibogaine on zebrafish: the developing utility of novel aquatic models for hallucinogenic drug research.2013 · Cachat J, Kyzar EJ, Collins C, Gaikwad S, Green J, Roth A, El-Ounsi M, Davis A, Pham M, Landsman S, Stewart AM, Kalueff AV.Behav Brain Res · MED 22974549 · DOI 10.1016/j.bbr.2012.08.041
• Thermostabilisation of the serotonin transporter in a cocaine-bound conformation.2013 · Abdul-Hussein S, Andréll J, Tate CG.J Mol Biol · MED 23706649 · DOI 10.1016/j.jmb.2013.03.025
• Ligand induced conformational changes of the human serotonin transporter revealed by molecular dynamics simulations.2013 · Koldsø H, Autzen HE, Grouleff J, Schiøtt B.PLoS One · MED 23776432 · DOI 10.1371/journal.pone.0063635
• Ibogaine related sudden death: a case report.2013 · Papadodima SA, Dona A, Evaggelakos CI, Goutas N, Athanaselis SA.J Forensic Leg Med · MED 24112325 · DOI 10.1016/j.jflm.2013.06.032
• Ibogaine in the treatment of substance dependence.2013 · Brown TK.Curr Drug Abuse Rev · MED 23627782 · DOI 10.2174/15672050113109990001
• Growing menace of ibogaine toxicity.2013 · Asua I.Br J Anaesth · MED 24233315 · DOI 10.1093/bja/aet396
• Fatal case of a 27-year-old male after taking iboga in withdrawal treatment: GC-MS/MS determination of ibogaine and ibogamine in iboga roots and postmortem biological material.2013 · Mazoyer C, Carlier J, Boucher A, Péoc'h M, Lemeur C, Gaillard Y.J Forensic Sci · MED 23919354 · DOI 10.1111/1556-4029.12250
• Effect of Iboga alkaloids on µ-opioid receptor-coupled G protein activation.2013 · Antonio T, Childers SR, Rothman RB, Dersch CM, King C, Kuehne M, Bornmann WG, Eshleman AJ, Janowsky A, Simon ER, Reith ME, Alper K.PLoS One · MED 24204784 · DOI 10.1371/journal.pone.0077262
• Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: a study to assess the drug's cardiac ion channel profile.2013 · Koenig X, Kovar M, Rubi L, Mike AK, Lukacs P, Gawali VS, Todt H, Hilber K, Sandtner W.Toxicol Appl Pharmacol · MED 23707769 · DOI 10.1016/j.taap.2013.05.012
• A case of death due to ibogaine use for heroin addiction: case report.2013 · Jalal S, Daher E, Hilu R.Am J Addict · MED 23617876 · DOI 10.1111/j.1521-0391.2012.00330.x
• α3β4 nicotinic acetylcholine receptors in the medial habenula modulate the mesolimbic dopaminergic response to acute nicotine in vivo.2012 · McCallum SE, Cowe MA, Lewis SW, Glick SD.Neuropharmacology · MED 22561751 · DOI 10.1016/j.neuropharm.2012.04.015
• [Study on the alkaloids constituents from Voacanga africana].2012 · Mei L, Deng Y, Li F, Guo DL, Lu CY.Zhong Yao Cai · MED 22822667
• The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters.2012 · Bulling S, Schicker K, Zhang YW, Steinkellner T, Stockner T, Gruber CW, Boehm S, Freissmuth M, Rudnick G, Sitte HH, Sandtner W.J Biol Chem · MED 22451652 · DOI 10.1074/jbc.m112.343681
• The anti-addiction drug ibogaine inhibits cardiac ion channels: a study to assess the drug’s proarrhythmic potential2012 · Koenig X, Kovar M, Rubi L, Mike Á, Lukács P, Gawali V, Todt H, Sandtner W, Hilber K.BMC Pharmacol Toxicol · PMC PMC3506296
• Phytotherapy of alcoholism.2012 · Tomczyk M, Zovko-Koncić M, Chrostek L.Nat Prod Commun · MED 22474979 · DOI 10.1177/1934578x1200700243
• Noribogaine compositions2012 · MASH DEBORAH C, MORIARTY ROBERT M.Support non renseigné dans l’index · PAT AU2010214685B
• NORIBOGAINE IN THE TREATMENT OF PAIN AND DRUG ADDICTION2012 · MASH DEBORAH C.Support non renseigné dans l’index · PAT US2012083485
• NORIBOGAINE COMPOSITIONS2012 · MORIARTY ROBERT M, MASH DEBORAH C.Support non renseigné dans l’index · PAT WO2012012764
• Metabolic plasticity and the energy economizing effect of ibogaine, the principal alkaloid of Tabernanthe iboga.2012 · Paškulin R, Jamnik P, Danevčič T, Koželj G, Krašovec R, Krstić-Milošević D, Blagojević D, Strukelj B.J Ethnopharmacol · MED 22751004 · DOI 10.1016/j.jep.2012.06.039
• Life-threatening complications of ibogaine: three case reports.2012 · Paling FP, Andrews LM, Valk GD, Blom HJ.Neth J Med · MED 23123541
• Ibogaine-associated ventricular tachyarrhythmias.2012 · Pleskovic A, Gorjup V, Brvar M, Kozelj G.Clin Toxicol (Phila) · MED 22304378 · DOI 10.3109/15563650.2011.647031
• Ibogaine and the inhibition of acetylcholinesterase.2012 · Alper K, Reith ME, Sershen H.J Ethnopharmacol · MED 22200647 · DOI 10.1016/j.jep.2011.12.006
• Fatalities temporally associated with the ingestion of ibogaine.2012 · Alper KR, Stajić M, Gill JR.J Forensic Sci · MED 22268458 · DOI 10.1111/j.1556-4029.2011.02008.x
• 18-Methoxycoronaridine blocks context-induced reinstatement following cocaine self-administration in rats.2012 · Polston JE, Pritchett CE, Sell EM, Glick SD.Pharmacol Biochem Behav · MED 22885280 · DOI 10.1016/j.pbb.2012.07.013
• The need for ibogaine in drug and alcohol addiction treatment.2011 · Donnelly JR.J Leg Med · MED 21391058 · DOI 10.1080/01947648.2011.550832
• Structure-activity relationship of ibogaine analogs interacting with nicotinic acetylcholine receptors in different conformational states.2011 · Arias HR, Feuerbach D, Targowska-Duda KM, Jozwiak K.Int J Biochem Cell Biol · MED 21642011 · DOI 10.1016/j.biocel.2011.05.011
• Sex differences in high fat-induced obesity in rats: Effects of 18-methoxycoronaridine.2011 · Taraschenko OD, Maisonneuve IM, Glick SD.Physiol Behav · MED 21324333 · DOI 10.1016/j.physbeh.2011.02.011
• Resistance of male Sprague-Dawley rats to sucrose-induced obesity: effects of 18-methoxycoronaridine.2011 · Taraschenko OD, Maisonneuve IM, Glick SD.Physiol Behav · MED 20951714 · DOI 10.1016/j.physbeh.2010.10.010
• Noribogaine in the treatment of pain and drug addiction2011 · MASH DEBORAH C.Support non renseigné dans l’index · PAT EP2338494
• Induction of insulin secretion by an aqueous extract of Tabernanhte iboga Baill. (Apocynaceae) in rat pancreatic islets of Langerhans.2011 · Souza A, Mbatchi B, Herchuelz A.J Ethnopharmacol · MED 21094242 · DOI 10.1016/j.jep.2010.11.028
• Ibogaine-associated psychosis in schizophrenia: a case report.2011 · Houenou J, Homri W, Leboyer M, Drancourt N.J Clin Psychopharmacol · MED 21881451 · DOI 10.1097/jcp.0b013e31822c6509
• Ibogaine--be informed before you promote or prescribe.2011 · Galea S, Lorusso M, Newcombe D, Walters C, Williman J, Wheeler A.J Prim Health Care · MED 21359272
• Effects of 18-methoxycoronaridine on ghrelin-induced increases in sucrose intake and accumbal dopamine overflow in female rats.2011 · McCallum SE, Taraschenko OD, Hathaway ER, Vincent MY, Glick SD.Psychopharmacology (Berl) · MED 21210086 · DOI 10.1007/s00213-010-2132-0
• Brain regions mediating α3β4 nicotinic antagonist effects of 18-MC on nicotine self-administration.2011 · Glick SD, Sell EM, McCallum SE, Maisonneuve IM.Eur J Pharmacol · MED 21871879 · DOI 10.1016/j.ejphar.2011.08.001
• Anesthesia for opiate detoxification and the ibogaine controversy.2011 · Gevirtz C.Int Anesthesiol Clin · MED 21239904 · DOI 10.1097/aia.0b013e3181ff4da0
• Analysis of electrical brain waves in neurotoxicology: γ-hydroxybutyrate.2011 · Binienda ZK, Beaudoin MA, Thorn BT, Ali SF.Curr Neuropharmacol · MED 21886596 · DOI 10.2174/157015911795017209
• 17th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint meeting with the Hungarian Society of Experimental and Clinical Pharmacology (MFT) Innsbruck, Austria. 29-30 September 2011. Abstracts.2011 · Auteurs non renseignés dans l’indexBMC Pharmacol · MED 21999824 · DOI 10.1186/1471-2210-11-s2-a1
• The high-affinity binding site for tricyclic antidepressants resides in the outer vestibule of the serotonin transporter.2010 · Sarker S, Weissensteiner R, Steiner I, Sitte HH, Ecker GF, Freissmuth M, Sucic S.Mol Pharmacol · MED 20829432 · DOI 10.1124/mol.110.067538
• Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration.2010 · Carnicella S, He DY, Yowell QV, Glick SD, Ron D.Addict Biol · MED 21040239 · DOI 10.1111/j.1369-1600.2010.00251.x
• Noribogaine in the treatment of pain and drug addiction2010 · MASH DEBORAH C.Support non renseigné dans l’index · PAT EP2246058
• NORIBOGAINE IN THE TREATMENT OF PAIN AND DRUG ADDICTION2010 · MASH DEBORAH C.Support non renseigné dans l’index · PAT US2010311722
• NORIBOGAINE IN THE TREATMENT OF PAIN AND DRUG ADDICTION2010 · MASH DEBORAH C.Support non renseigné dans l’index · PAT US2010311723
• NORIBOGAINE IN THE TREATMENT OF PAIN AND DRUG ADDICTION2010 · MASH DEBORAH C.Support non renseigné dans l’index · PAT US2010311725
• NORIBOGAINE IN THE TREATMENT OF PAIN AND DRUG ADDICTION2010 · MASH DEBORAH C.Support non renseigné dans l’index · PAT US2010311724
• Mutations in the carboxyl-terminal SEC24 binding motif of the serotonin transporter impair folding of the transporter.2010 · El-Kasaby A, Just H, Malle E, Stolt-Bergner PC, Sitte HH, Freissmuth M, Kudlacek O.J Biol Chem · MED 20889976 · DOI 10.1074/jbc.m110.118000
• Interaction of ibogaine with human alpha3beta4-nicotinic acetylcholine receptors in different conformational states.2010 · Arias HR, Rosenberg A, Targowska-Duda KM, Feuerbach D, Yuan XJ, Jozwiak K, Moaddel R, Wainer IW.Int J Biochem Cell Biol · MED 20684041 · DOI 10.1016/j.biocel.2010.05.011
• Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).2010 · Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Declèves X.Int J Neuropsychopharmacol · MED 19887017 · DOI 10.1017/s1461145709990848
• Interaction of 18-methoxycoronaridine with nicotinic acetylcholine receptors in different conformational states.2010 · Arias HR, Rosenberg A, Feuerbach D, Targowska-Duda KM, Maciejewski R, Jozwiak K, Moaddel R, Glick SD, Wainer IW.Biochim Biophys Acta · MED 20303928 · DOI 10.1016/j.bbamem.2010.03.013
• Induction of energy metabolism related enzymes in yeast Saccharomyces cerevisiae exposed to ibogaine is adaptation to acute decrease in ATP energy pool.2010 · Paskulin R, Jamnik P, Obermajer N, Slavić M, Strukelj B.Eur J Pharmacol · MED 19853595 · DOI 10.1016/j.ejphar.2009.10.032
• Catharanthine alkaloids are noncompetitive antagonists of muscle-type nicotinic acetylcholine receptors.2010 · Arias HR, Feuerbach D, Targowska-Duda KM, Jozwiak K.Neurochem Int · MED 20493225 · DOI 10.1016/j.neuint.2010.05.007
• A new indole alkaloid from Ervatamia yunnanensis.2010 · Jin YS, Du JL, Chen HS, Jin L, Liang S.Fitoterapia · MED 19647051 · DOI 10.1016/j.fitote.2009.07.008
• 18-Methoxycoronaridine, a potential anti-obesity agent, does not produce a conditioned taste aversion in rats.2010 · Taraschenko OD, Maisonneuve IM, Glick SD.Pharmacol Biochem Behav · MED 20457177 · DOI 10.1016/j.pbb.2010.05.002
• [Chemical and DNA analyses for the products of a psychoactive plant, Voacanga africana].2009 · Kikura-Hanajiri R, Maruyama T, Miyashita A, Goda Y.Yakugaku Zasshi · MED 19652504 · DOI 10.1248/yakushi.129.975
• Long-QT syndrome induced by the antiaddiction drug ibogaine.2009 · Hoelen DW, Spiering W, Valk GD.N Engl J Med · MED 19144953 · DOI 10.1056/nejmc0804248
• Ibogaine labeling with 99mTc-tricarbonyl: synthesis and transport at the mouse blood-brain barrier.2009 · Tournier N, André P, Blondeel S, Rizzo-Padoin N, du Moulinet d'Hardemarre A, Declèves X, Scherrmann JM, Cisternino S.J Pharm Sci · MED 19492342 · DOI 10.1002/jps.21771
• Bioanalytical and clinical evaluation of 103 suspected cases of intoxications with psychoactive plant materials.2009 · Björnstad K, Hultén P, Beck O, Helander A.Clin Toxicol (Phila) · MED 19586355 · DOI 10.1080/15563650903037181
• Analysis of toxic alkaloids in body samples.2009 · Beyer J, Drummer OH, Maurer HH.Forensic Sci Int · MED 19147309 · DOI 10.1016/j.forsciint.2008.12.006
• A multi-component LC-MS/MS method for detection of ten plant-derived psychoactive substances in urine.2009 · Björnstad K, Beck O, Helander A.J Chromatogr B Analyt Technol Biomed Life Sci · MED 19332394 · DOI 10.1016/j.jchromb.2009.03.004
• 18-Methoxycoronaridine blocks acquisition but enhances reinstatement of a cocaine place preference.2009 · McCallum SE, Glick SD.Neurosci Lett · MED 19442876 · DOI 10.1016/j.neulet.2009.04.019
• The near-death experience: a cerebellar method to protect body and soul-lessons from the Iboga healing ceremony in Gabon.2008 · Strubelt S, Maas U.Altern Ther Health Med · MED 18251319
• The ibogaine medical subculture.2008 · Alper KR, Lotsof HS, Kaplan CD.J Ethnopharmacol · MED 18029124 · DOI 10.1016/j.jep.2007.08.034
• Simultaneous determination of thirteen plant alkaloids in a human specimen by SPE and HPLC.2008 · Pietsch J, Günther J, Henle T, Dressler J.J Sep Sci · MED 18601225 · DOI 10.1002/jssc.200800128
• N-(Hydroxymethyl)ibogaine.2008 · Jarraya RM, Bouaziz A, Hamdi B, Ben Salah A, Damak M.Acta Crystallogr Sect E Struct Rep Online · MED 21201722 · DOI 10.1107/s1600536808025324
• Inhibition of Candida albicans extracellular enzyme activity by selected natural substances and their application in Candida infection.2008 · Yordanov M, Dimitrova P, Dimitrova P, Patkar S, Saso L, Ivanovska N.Can J Microbiol · MED 18535628 · DOI 10.1139/w08-029
• Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review.2008 · Maciulaitis R, Kontrimaviciute V, Bressolle FM, Briedis V.Hum Exp Toxicol · MED 18650249 · DOI 10.1177/0960327107087802
• GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse.2008 · Carnicella S, Kharazia V, Jeanblanc J, Janak PH, Ron D.Proc Natl Acad Sci U S A · MED 18541917 · DOI 10.1073/pnas.0711755105
• Determination of ibogaine and noribogaine in biological fluids and hair by LC-MS/MS after Tabernanthe iboga abuse Iboga alkaloids distribution in a drowning death case.2008 · Chèze M, Lenoan A, Deveaux M, Pépin G.Forensic Sci Int · MED 18024037 · DOI 10.1016/j.forsciint.2007.08.013
• COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C AND METHODS FOR USING COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C2008 · LOTSOF HOWARD L.Support non renseigné dans l’index · PAT WO2008039179
• COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C AND METHODS FOR USING COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C2008 · LOTSOF HOWARD L.Support non renseigné dans l’index · PAT CA2664935
• Brain regions mediating alpha3beta4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration.2008 · Glick SD, Sell EM, Maisonneuve IM.Eur J Pharmacol · MED 18930043 · DOI 10.1016/j.ejphar.2008.09.038
• Acute toxicity of ibogaine and noribogaine.2008 · Kubiliene A, Marksiene R, Kazlauskas S, Sadauskiene I, Razukas A, Ivanov L.Medicina (Kaunas) · MED 19142057 · DOI 10.3390/medicina44120123
• 18-methoxycoronaridine: a potential new treatment for obesity in rats?2008 · Taraschenko OD, Rubbinaccio HY, Maisonneuve IM, Glick SD.Psychopharmacology (Berl) · MED 18751969 · DOI 10.1007/s00213-008-1290-9
• [Study on chemical constituents in rhigome of Ervatamia hainanensis].2007 · Liang S, Chen HS, Jin YS, Jin L, Lu J, Du JL.Zhongguo Zhong Yao Za Zhi · MED 17879729
• Treatment with Sigma Receptor Agonists Post-Stroke2007 · PENNYPACKER KEITH R, CUEVAS JAVIER.Support non renseigné dans l’index · PAT US2007123556
• Synthesis of isoquinuclidine analogs of chloroquine: antimalarial and antileishmanial activity.2007 · Khan MO, Levi MS, Tekwani BL, Wilson NH, Borne RF.Bioorg Med Chem · MED 17400457 · DOI 10.1016/j.bmc.2006.11.024
• Noribogaine in the treatment of pain and drug addiction2007 · MASH DEBORAH C.Support non renseigné dans l’index · PAT US2007185085
• Noribogaine in the treatment of pain and drug addiction2007 · MASH DEBORAH C.Support non renseigné dans l’index · PAT US7220737
• Morphine-induced changes in acetylcholine release in the interpeduncular nucleus and relationship to changes in motor behavior in rats.2007 · Taraschenko OD, Rubbinaccio HY, Shulan JM, Glick SD, Maisonneuve IM.Neuropharmacology · MED 17544456 · DOI 10.1016/j.neuropharm.2007.04.010
• Liquid chromatography-tandem mass spectrometry method for the simultaneous analysis of multiple hallucinogens, chlorpheniramine, ketamine, ritalinic acid, and metabolites, in urine.2007 · del Mar Ramirez Fernandez M, Laloup M, Wood M, De Boeck G, Lopez-Rivadulla M, Wallemacq P, Samyn N.J Anal Toxicol · MED 17988464 · DOI 10.1093/jat/31.8.497
• Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter.2007 · Jacobs MT, Zhang YW, Campbell SD, Rudnick G.J Biol Chem · MED 17698848 · DOI 10.1074/jbc.m704456200
• Client and counselor attitudes toward the use of medications for treatment of opioid dependence.2007 · Rieckmann T, Daley M, Fuller BE, Thomas CP, McCarty D.J Subst Abuse Treat · MED 17306729 · DOI 10.1016/j.jsat.2006.09.002
• 18-MC acts in the medial habenula and interpeduncular nucleus to attenuate dopamine sensitization to morphine in the nucleus accumbens.2007 · Taraschenko OD, Shulan JM, Maisonneuve IM, Glick SD.Synapse · MED 17447255 · DOI 10.1002/syn.20396
• The adverse effects of hallucinogens from intramural perspective.2006 · Frecska E, Luna LE.Neuropsychopharmacol Hung · MED 17211054
• TREATMENT WITH SIGMA RECEPTOR AGONISTS POST-STROKE2006 · PENNYPACKER KEITH R, CUEVAS JAVIER.Support non renseigné dans l’index · PAT CA2607598
• TREATMENT WITH SIGMA RECEPTOR AGONISTS POST-STROKE2006 · PENNYPACKER Keith R., CUEVAS Javier.Support non renseigné dans l’index · PAT WO2006133199
• Subtypes of neuronal nicotinic acetylcholine receptors involved in nicotine-induced phosphorylation of extracellular signal-regulated protein kinase in PC12h cells.2006 · Nakayama H, Shimoke K, Isosaki M, Satoh H, Yoshizumi M, Ikeuchi T.Neurosci Lett · MED 16219421 · DOI 10.1016/j.neulet.2005.09.003
• Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia.2006 · Katnik C, Guerrero WR, Pennypacker KR, Herrera Y, Cuevas J.J Pharmacol Exp Ther · MED 16988055 · DOI 10.1124/jpet.106.107557
• Noribogaine in the treatment of pain and drug addiction2006 · MASH DEBORAH C.Support non renseigné dans l’index · PAT AU2003200404B
• Nature-inspired indolyl-2-azabicyclo[2.2.2]oct-7-ene derivatives as promising agents for the attenuation of withdrawal symptoms: synthesis of 20-desethyl-20-hydroxymethyl-11-demethoxyibogaine.2006 · Passarella D, Barilli A, Efange SM, Elisabetsky E, Leal MB, Lesma G, Linck VM, Mash DC, Martinelli M, Peretto I, Silvani A, Danieli B.Nat Prod Res · MED 16753910 · DOI 10.1080/14786410500160645
• Modulation of high alcohol drinking in the inbred Fawn-Hooded (FH/Wjd) rat strain: implications for treatment.2006 · Overstreet DH, Rezvani AH, Cowen M, Chen F, Lawrence AJ.Addict Biol · MED 16961764 · DOI 10.1111/j.1369-1600.2006.00033.x
• Liquid chromatography-electrospray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood. Application to a poisoning involving Tabernanthe iboga root.2006 · Kontrimaviciūte V, Breton H, Mathieu O, Mathieu-Daudé JC, Bressolle FM.J Chromatogr B Analyt Technol Biomed Life Sci · MED 16798116 · DOI 10.1016/j.jchromb.2006.05.035
• Ibogaine may help drug addicts live the 'never again'.2006 · Bateman C.S Afr Med J · MED 16909175 · DOI 10.7196/samj.1185
• Ibogaine affects brain energy metabolism.2006 · Paskulin R, Jamnik P, Zivin M, Raspor P, Strukelj B.Eur J Pharmacol · MED 17054944 · DOI 10.1016/j.ejphar.2006.09.008
• Gateways to clinical trials.2006 · Bayés M, Rabasseda X, Prous JR.Methods Find Exp Clin Pharmacol · MED 16801985
• Fatalities after taking ibogaine in addiction treatment could be related to sudden cardiac death caused by autonomic dysfunction.2006 · Maas U, Strubelt S.Med Hypotheses · MED 16698188 · DOI 10.1016/j.mehy.2006.02.050
• Distribution of ibogaine and noribogaine in a man following a poisoning involving root bark of the Tabernanthe iboga shrub.2006 · Kontrimaviciūte V, Mathieu O, Mathieu-Daudé JC, Vainauskas P, Casper T, Baccino E, Bressolle FM.J Anal Toxicol · MED 16959135 · DOI 10.1093/jat/30.7.434
• Complementary medicines in psychiatry: review of effectiveness and safety.2006 · Werneke U, Turner T, Priebe S.Br J Psychiatry · MED 16449696 · DOI 10.1192/bjp.188.2.109
• Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine.2006 · He DY, Ron D.FASEB J · MED 17023388 · DOI 10.1096/fj.06-6394fje
• 18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats.2006 · Glick SD, Ramirez RL, Livi JM, Maisonneuve IM.Eur J Pharmacol · MED 16626688 · DOI 10.1016/j.ejphar.2006.03.045
• sigma Receptor activation blocks potassium channels and depresses neuroexcitability in rat intracardiac neurons.2005 · Zhang H, Cuevas J.J Pharmacol Exp Ther · MED 15764734 · DOI 10.1124/jpet.105.084152
• Quantitation of ibogaine and 12-hydroxyibogamine in human plasma by liquid chromatography with fluorimetric detection.2005 · Kontrimaviciūte V, Larroque M, Briedis V, Margout D, Bressolle F.J Chromatogr B Analyt Technol Biomed Life Sci · MED 16002351 · DOI 10.1016/j.jchromb.2005.06.018
• Nicotinic agonists, antagonists, and modulators from natural sources.2005 · Daly JW.Cell Mol Neurobiol · MED 16075378 · DOI 10.1007/s10571-005-3968-4
• Mitigating symptoms and behaviors of substance abuse by modulating GDNF or BDNF pathway activity2005 · RON DORIT.Support non renseigné dans l’index · PAT US2005203011
• Is antagonism of alpha3beta4 nicotinic receptors a strategy to reduce morphine dependence?2005 · Taraschenko OD, Panchal V, Maisonneuve IM, Glick SD.Eur J Pharmacol · MED 15862802 · DOI 10.1016/j.ejphar.2005.03.005
• Indole alkaloids from Tabernaemontana australis (Muell. Arg) Miers that inhibit acetylcholinesterase enzyme.2005 · Andrade MT, Lima JA, Pinto AC, Rezende CM, Carvalho MP, Epifanio RA.Bioorg Med Chem · MED 15911323 · DOI 10.1016/j.bmc.2005.03.045
• Ibogaine reduces organ colonization in murine systemic and gastrointestinal Candida albicans infections.2005 · Yordanov M, Dimitrova P, Dimitrova P, Patkar S, Falcocchio S, Xoxi E, Saso L, Ivanovska N.J Med Microbiol · MED 15947429 · DOI 10.1099/jmm.0.45919-0
• Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption.2005 · He DY, McGough NN, Ravindranathan A, Jeanblanc J, Logrip ML, Phamluong K, Janak PH, Ron D.J Neurosci · MED 15659598 · DOI 10.1523/jneurosci.3959-04.2005
• Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine.2005 · Panchal V, Taraschenko OD, Maisonneuve IM, Glick SD.Eur J Pharmacol · MED 16289028 · DOI 10.1016/j.ejphar.2005.09.060
• Addiction research. Ibogaine therapy: a 'vast, uncontrolled experiment'.2005 · Vastag B.Science · MED 15831735 · DOI 10.1126/science.308.5720.345
• [Ibogaine--the substance for treatment of toxicomania. Neurochemical and pharmacological action].2004 · Kazlauskas S, Kontrimaviciūte V, Sveikata A.Medicina (Kaunas) · MED 15064541
• Use of CYP2D6 inhibitors in combination therapies2004 · OBACH RONALD SCOTT.Support non renseigné dans l’index · PAT NZ514466
• USE OF CYP2D62004 · OBACH RONALD SCOTT.Support non renseigné dans l’index · PAT EA005158
• Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration.2004 · Pace CJ, Glick SD, Maisonneuve IM, He LW, Jokiel PA, Kuehne ME, Fleck MW.Eur J Pharmacol · MED 15178360 · DOI 10.1016/j.ejphar.2004.03.062
• Methods and compositions for treating addiction disorders2004 · GLICK STANLEY D, MAISONNEUVE ISABELLE M.Support non renseigné dans l’index · PAT US6780871
• Differential effects of ibogaine on local cerebral glucose utilization in drug-naive and morphine-dependent rats.2004 · Levant B, Pazdernik TL.Brain Res · MED 15019575 · DOI 10.1016/j.brainres.2003.12.032
• Combating substance abuse with ibogaine: pre- and posttreatment recommendations and an example of successive model fitting analyses.2004 · Hittner JB, Quello SB.J Psychoactive Drugs · MED 15369200 · DOI 10.1080/02791072.2004.10399729
• Anti-HIV-1 activity of the Iboga alkaloid congener 18-methoxycoronaridine.2004 · Silva EM, Cirne-Santos CC, Frugulhetti IC, Galvão-Castro B, Saraiva EM, Kuehne ME, Bou-Habib DC.Planta Med · MED 15386189 · DOI 10.1055/s-2004-827227
• Administration of a non-NMDA antagonist, GYKI 52466, increases excitotoxic Purkinje cell degeneration caused by ibogaine.2004 · O'Hearn E, Molliver ME.Neuroscience · MED 15262328 · DOI 10.1016/j.neuroscience.2004.04.058
• Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents.2003 · Kuehne ME, He L, Jokiel PA, Pace CJ, Fleck MW, Maisonneuve IM, Glick SD, Bidlack JM.J Med Chem · MED 12801235 · DOI 10.1021/jm020562o
• Plants and the central nervous system.2003 · Carlini EA.Pharmacol Biochem Behav · MED 12895668 · DOI 10.1016/s0091-3057(03)00112-6
• Plant derivatives in the treatment of alcohol dependency.2003 · Rezvani AH, Overstreet DH, Perfumi M, Massi M.Pharmacol Biochem Behav · MED 12895677 · DOI 10.1016/s0091-3057(03)00124-2
• Noribogaine in the treatment of pain and drug addiction2003 · Mash Deborah C..Support non renseigné dans l’index · PAT EP1327447
• Method of treating chemical dependency in mammals and a composition therefor2003 · MASH DEBORAH C, SANCHEZ-RAMOS JUAN, HEARN WILLIAM LEE.Support non renseigné dans l’index · PAT US2003153552
• Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-D-aspartate receptors.2003 · Leal MB, Michelin K, Souza DO, Elisabetsky E.Prog Neuropsychopharmacol Biol Psychiatry · MED 12921910 · DOI 10.1016/s0278-5846(03)00109-x
• Ibogaine analogues. Synthesis and preliminary pharmacological evaluation of 7-heteroaryl-2-azabicyclo[2.2.2]oct-7-enes.2003 · Passarella D, Favia R, Giardini A, Lesma G, Martinelli M, Silvani A, Danieli B, Efange SM, Mash DC.Bioorg Med Chem · MED 12614886 · DOI 10.1016/s0968-0896(02)00524-2
• Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment.2003 · Maisonneuve IM, Glick SD.Pharmacol Biochem Behav · MED 12895678 · DOI 10.1016/s0091-3057(03)00119-9
• Affinity and specificity of N-methyl- D-aspartate channel blockers affect their ability to disrupt prepulse inhibition of acoustic startle in rats.2003 · Wiley JL, Harvey SA, Balster RL, Nicholson KL.Psychopharmacology (Berl) · MED 12459931 · DOI 10.1007/s00213-002-1297-6
• Why do Purkinje cells die so easily after global brain ischemia? Aldolase C, EAAT4, and the cerebellar contribution to posthypoxic myoclonus.2002 · Welsh JP, Yuen G, Placantonakis DG, Vu TQ, Haiss F, O'Hearn E, Molliver ME, Aicher SA.Adv Neurol · MED 11968459
• Sigma receptors inhibit high-voltage-activated calcium channels in rat sympathetic and parasympathetic neurons.2002 · Zhang H, Cuevas J.J Neurophysiol · MED 12037190 · DOI 10.1152/jn.2002.87.6.2867
• Modulation of nicotine self-administration in rats by combination therapy with agents blocking alpha 3 beta 4 nicotinic receptors.2002 · Glick SD, Maisonneuve IM, Kitchen BA.Eur J Pharmacol · MED 12144940 · DOI 10.1016/s0014-2999(02)01944-1
• Methods and compositions for treating addiction disorders2002 · GLICK STANLEY D, MAISONNEUVE ISABELLE M.Support non renseigné dans l’index · PAT US2002103109
• Method of treating chemical dependency in mammals and a composition therefor2002 · MASH DEBORAH C, SANCHEZ-RAMOS JUAN, HEARN W LEE.Support non renseigné dans l’index · PAT US6348456
• Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19.2002 · Zhang W, Ramamoorthy Y, Tyndale RF, Glick SD, Maisonneuve IM, Kuehne ME, Sellers EM.Drug Metab Dispos · MED 12019193 · DOI 10.1124/dmd.30.6.663
• METHODS AND COMPOSITIONS FOR TREATING ADDICTION DISORDERS2002 · GLICK Stanley D., MAISONNEUVE Isabelle M..Support non renseigné dans l’index · PAT WO02060425
• In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis.2002 · Delorenzi JC, Freire-de-Lima L, Gattass CR, de Andrade Costa D, He L, Kuehne ME, Saraiva EM.Antimicrob Agents Chemother · MED 12069962 · DOI 10.1128/aac.46.7.2111-2115.2002
• Ibogaine signals addiction genes and methamphetamine alteration of long-term potentiation.2002 · Onaivi ES, Ali SF, Chirwa SS, Zwiller J, Thiriet N, Akinshola BE, Ishiguro H.Ann N Y Acad Sci · MED 12105083 · DOI 10.1111/j.1749-6632.2002.tb04149.x
• Ibogaine interferes with motivational and somatic effects of naloxone-precipitated withdrawal from acutely administered morphine.2002 · Parke LA, Burton P, McDonald RV, Kim JA, Siegel S.Prog Neuropsychopharmacol Biol Psychiatry · MED 11817506 · DOI 10.1016/s0278-5846(01)00268-8
• Hallucinogens and redemption.2002 · de Rios MD, Grob CS, Baker JR.J Psychoactive Drugs · MED 12422934 · DOI 10.1080/02791072.2002.10399960
• Formulations and use of controlled-release indole alkaloids2002 · ZELIGS MICHAEL A, JACOBS IRWIN C.Support non renseigné dans l’index · PAT US6416793
• Extraction studies of Tabernanthe iboga and Voacanga africana.2002 · Jenks CW.Nat Prod Lett · MED 11942686 · DOI 10.1080/1057563029001/4881
• Characterization of the discriminable stimulus produced by 2-BFI: effects of imidazoline I(2)-site ligands, MAOIs, beta-carbolines, agmatine and ibogaine.2002 · MacInnes N, Handley SL.Br J Pharmacol · MED 11877331 · DOI 10.1038/sj.bjp.0704579
• Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration.2002 · Glick SD, Maisonneuve IM, Kitchen BA, Fleck MW.Eur J Pharmacol · MED 11906717 · DOI 10.1016/s0014-2999(02)01284-0
• A review of chemical agents in the pharmacotherapy of addiction.2002 · Levi MS, Borne RF.Curr Med Chem · MED 12369879 · DOI 10.2174/0929867023368980
• Modulation of the effects of rewarding drugs by ibogaine.2001 · Parker LA, Siegel S.Alkaloids Chem Biol · MED 11705109 · DOI 10.1016/s0099-9598(01)56015-0
• Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener.2001 · Glick SD, Maisonneuve IM, Szumlinski KK.Alkaloids Chem Biol · MED 11705115 · DOI 10.1016/s0099-9598(01)56006-x
• In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats.2001 · Baumann MH, Rothman RB, Pablo JP, Mash DC.J Pharmacol Exp Ther · MED 11303040 · DOI 10.1016/s0022-3565(24)29567-7
• Ibogaine: proceedings of the First International Conference.2001 · Kleber H.Alkaloids Chem Biol · MED 11705119
• Ibogaine: a review.2001 · Alper KR.Alkaloids Chem Biol · MED 11705103 · DOI 10.1016/s0099-9598(01)56005-8
• Ibogaine neurotoxicity assessment: electrophysiological, neurochemical, and neurohistological methods.2001 · Binienda ZK, Scallet AC, Schmued LC, Ali SF.Alkaloids Chem Biol · MED 11705108 · DOI 10.1016/s0099-9598(01)56014-9
• Ibogaine in the treatment of heroin withdrawal.2001 · Mash DC, Kovera CA, Pablo J, Tyndale R, Ervin FR, Kamlet JD, Hearn WL.Alkaloids Chem Biol · MED 11705106 · DOI 10.1016/s0099-9598(01)56012-5
• Ibogaine as a glutamate antagonist: relevance to its putative antiaddictive properties.2001 · Skolnick P.Alkaloids Chem Biol · MED 11705116 · DOI 10.1016/s0099-9598(01)56007-1
• Ibogaine alters synaptosomal and glial glutamate release and uptake.2001 · Leal MB, Emanuelli T, Porciúncula LD, Souza DO, Elisabetsky E.Neuroreport · MED 11209932 · DOI 10.1097/00001756-200102120-00017
• Iboga interactions with psychomotor stimulants: panacea in the paradox?2001 · Szumlinski KK, Maisonneuve IM, Glick SD.Toxicon · MED 10936624 · DOI 10.1016/s0041-0101(00)00158-6
• Iboga compounds reverse the behavioural disinhibiting and corticosterone effects of acute methamphetamine: Implications for their antiaddictive properties.2001 · Szumlinski KK, Haskew RE, Balogun MY, Maisonneuve IM, Glick SD.Pharmacol Biochem Behav · MED 11509208 · DOI 10.1016/s0091-3057(01)00564-0
• From the roots up: ibogaine and addict self-help.2001 · Frenken G.Alkaloids Chem Biol · MED 11705113 · DOI 10.1016/s0099-9598(01)56019-8
• Fluoro-Jade and silver methods: application to the neuropathology of scrapie, a transmissible spongiform encephalopathy.2001 · Ye X, Carp RI, Schmued LC, Scallet AC.Brain Res Brain Res Protoc · MED 11673092 · DOI 10.1016/s1385-299x(01)00086-1
• Evaluation of neurodegeneration in scrapie-infected animals by selective methods that detect cellular degeneration.2001 · Ye X, Rountree R, Scallet A, Meeker HC, Carp RI.Brain Res · MED 11489267 · DOI 10.1016/s0006-8993(01)02616-6
• Drug discrimination studies with ibogaine.2001 · Helsley S, Rabin RA, Winter JC.Alkaloids Chem Biol · MED 11705117 · DOI 10.1016/s0099-9598(01)56008-3
• Differential neuronal localizations and dynamics of phosphorylated and unphosphorylated type 1 inositol 1,4,5-trisphosphate receptors.2001 · Pieper AA, Brat DJ, O'Hearn E, Krug DK, Kaplin AI, Takahashi K, Greenberg JH, Ginty D, Molliver ME, Snyder SH.Neuroscience · MED 11166129 · DOI 10.1016/s0306-4522(00)00470-x
• Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine.2001 · Baumann MH, Pablo J, Ali SF, Rothman RB, Mash DC.Alkaloids Chem Biol · MED 11705118 · DOI 10.1016/s0099-9598(01)56009-5
• Characterization of multiple sites of action of ibogaine.2001 · Sershen H, Hashim A, Lajtha A.Alkaloids Chem Biol · MED 11705104 · DOI 10.1016/s0099-9598(01)56010-1
• Changes in gene expression and signal transduction following ibogaine treatment.2001 · Onaivi ES, Akinshola BE, Ali SF.Alkaloids Chem Biol · MED 11705105 · DOI 10.1016/s0099-9598(01)56011-3
• Case studies of ibogaine treatment: implications for patient management strategies.2001 · Lotsof HS, Alexander NE.Alkaloids Chem Biol · MED 11705114 · DOI 10.1016/s0099-9598(01)56020-4
• Anxiogenic action of ibogaine.2001 · Popik P, Wróbel M.Alkaloids Chem Biol · MED 11705110 · DOI 10.1016/s0099-9598(01)56016-2
• A contemporary history of ibogaine in the United States and Europe.2001 · Alper KR, Beal D, Kaplan CD.Alkaloids Chem Biol · MED 11705112 · DOI 10.1016/s0099-9598(01)56018-6
• The potential anti-addictive agent, 18-methoxycoronaridine, blocks the sensitized locomotor and dopamine responses produced by repeated morphine treatment.2000 · Szumlinski KK, Maisonneuve IM, Glick SD.Brain Res · MED 10793182 · DOI 10.1016/s0006-8993(00)02069-2
• The development and expression of locomotor sensitization to nicotine in the presence of ibogaine.2000 · Zubaran C, Shoaib M, Stolerman IP.Behav Pharmacol · MED 11103895 · DOI 10.1097/00008877-200008000-00009
• Synthesis of enantiomerically pure (+)- and (-)-18-methoxycoronaridine hydrochloride and their preliminary assessment as anti-addictive agents.2000 · King CH, Meckler H, Herr RJ, Trova MP, Glick SD, Maisonneuve IM.Bioorg Med Chem Lett · MED 10743951 · DOI 10.1016/s0960-894x(00)00033-0
• Responses of the extrapyramidal and limbic substance P systems to ibogaine and cocaine treatments.2000 · Alburges ME, Ramos BP, Bush L, Hanson GR.Eur J Pharmacol · MED 10708715 · DOI 10.1016/s0014-2999(99)00919-x
• Potential use of medicinal plants in the treatment of alcoholism.2000 · Carai MA, Agabio R, Bombardelli E, Bourov I, Gessa GL, Lobina C, Morazzoni P, Pani M, Reali R, Vacca G, Colombo G.Fitoterapia · MED 10930711 · DOI 10.1016/s0367-326x(00)00178-7
• Pharmacological comparison of the effect of ibogaine and 18-methoxycoronaridine on isolated smooth muscle from the rat and guinea-pig.2000 · Mundey MK, Blaylock NA, Mason R, Glick SD, Maisonneuve IM, Wilson VG.Br J Pharmacol · MED 10780959 · DOI 10.1038/sj.bjp.0703227
• Pharmacokinetic characterization of the indole alkaloid ibogaine in rats.2000 · Hough LB, Bagal AA, Glick SD.Methods Find Exp Clin Pharmacol · MED 10849889 · DOI 10.1358/mf.2000.22.2.796066
• Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine.2000 · Baumann MH, Pablo JP, Ali SF, Rothman RB, Mash DC.Ann N Y Acad Sci · MED 11085335 · DOI 10.1111/j.1749-6632.2000.tb05210.x
• NORIBOGAINE IN THE TREATMENT OF PAIN AND DRUG ADDICTION2000 · MASH Deborah C..Support non renseigné dans l’index · PAT EP1009407
• Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells.2000 · Vilner BJ, Bowen WD.J Pharmacol Exp Ther · MED 10688603 · DOI 10.1016/s0022-3565(24)35369-8
• Long-lasting ibogaine protection against NMDA-induced convulsions in mice.2000 · Leal MB, de Souza DO, Elisabetsky E.Neurochem Res · MED 11055745 · DOI 10.1023/a:1007665911622
• Interactions between iboga agents and methamphetamine sensitization: studies of locomotion and stereotypy in rats.2000 · Szumlinski KK, Balogun MY, Maisonneuve IM, Glick SD.Psychopharmacology (Berl) · MED 10972470 · DOI 10.1007/s002130000478
• Interactions between 18-methoxycoronaridine (18-MC) and cocaine: dissociation of behavioural and neurochemical sensitization.2000 · Szumlinski KK, McCafferty CA, Maisonneuve IM, Glick SD.Brain Res · MED 10899291 · DOI 10.1016/s0006-8993(00)02424-0
• In vivo and in vitro aspects of imidazoline-2(1/2)sites within the central nervous system2000 · MacInnes N.Support non renseigné dans l’index · ETH 544848 · DOI 10.48780/publications.aston.ac.uk.00010992
• Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.2000 · Mash DC, Kovera CA, Pablo J, Tyndale RF, Ervin FD, Williams IC, Singleton EG, Mayor M.Ann N Y Acad Sci · MED 11085338 · DOI 10.1111/j.1749-6632.2000.tb05213.x
• Ibogaine in acute opioid withdrawal. An open label case series.2000 · Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J.Ann N Y Acad Sci · MED 10911935 · DOI 10.1111/j.1749-6632.2000.tb06687.x
• Fluoro-Jade: novel fluorochromes for detecting toxicant-induced neuronal degeneration.2000 · Schmued LC, Hopkins KJ.Toxicol Pathol · MED 10668994 · DOI 10.1177/019262330002800111
• Differential effects of ibogaine on behavioural and dopamine sensitization to cocaine.2000 · Szumlinski KK, Maisonneuve IM, Glick SD.Eur J Pharmacol · MED 10854838 · DOI 10.1016/s0014-2999(00)00325-3
• Development of novel medications for drug addiction. The legacy of an African shrub.2000 · Glick SD, Maisonneuve IM.Ann N Y Acad Sci · MED 10911925 · DOI 10.1111/j.1749-6632.2000.tb06677.x
• Comparative neurobiological effects of ibogaine and MK-801 in rats.2000 · Baumann MH, Rothman RB, Ali SF.Drug Alcohol Depend · MED 10891627 · DOI 10.1016/s0376-8716(99)00113-1
• Application of electrophysiological method to study interactions between ibogaine and cocaine.2000 · Binienda Z, Beaudoin MA, Thorn BT, Sadovova N, Skinner RD, Slikker W, Ali SF.Ann N Y Acad Sci · MED 11085337 · DOI 10.1111/j.1749-6632.2000.tb05212.x
• A dose-response study of ibogaine-induced neuropathology in the rat cerebellum.2000 · Xu Z, Chang LW, Slikker W, Ali SF, Rountree RL, Scallet AC.Toxicol Sci · MED 10966515 · DOI 10.1093/toxsci/57.1.95
• 18-Methoxycoronaridine differentially alters the sensitized behavioral and dopaminergic responses to repeated cocaine and morphine administration. Implications for sensitization in the mediation of drug addiction.2000 · Szumlinski KK, Maisonneuve IM, Glick SD.Ann N Y Acad Sci · MED 10911941 · DOI 10.1111/j.1749-6632.2000.tb06694.x
• 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.2000 · Glick SD, Maisonneuve IM, Szumlinski KK.Ann N Y Acad Sci · MED 11085336 · DOI 10.1111/j.1749-6632.2000.tb05211.x
• 18-MC reduces methamphetamine and nicotine self-administration in rats.2000 · Glick SD, Maisonneuve IM, Dickinson HA.Neuroreport · MED 10884062 · DOI 10.1097/00001756-200006260-00041
• Use of ibogaine for treating neuropathic pain1999 · OLNEY JOHN W.Support non renseigné dans l’index · PAT US5925634
• Treatment of acute opioid withdrawal with ibogaine.1999 · Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J.Am J Addict · MED 10506904 · DOI 10.1080/105504999305848
• The effects of ibogaine on dopamine and serotonin transport in rat brain synaptosomes.1999 · Wells GB, Lopez MC, Tanaka JC.Brain Res Bull · MED 10386845 · DOI 10.1016/s0361-9230(99)00053-2
• The acute effects of monoamine reuptake inhibitors on the stimulus effects of hallucinogens.1999 · Winter JC, Helsley S, Fiorella D, Rabin RA.Pharmacol Biochem Behav · MED 10418794 · DOI 10.1016/s0091-3057(99)00039-8
• TRICYCLIC IBOGAINE ANALOGS, THEIR PREPARATION AND THEIR USE IN TREATING SUBSTANCE ABUSE1999 · EFANGE S. Mbua Ngale, MASH Deborah Carmen.Support non renseigné dans l’index · PAT EP0910567
• Pretreatment with the putative anti-addictive drug, ibogaine, increases the potency of cocaine to elicit locomotor responding: a study with acute and chronic cocaine-treated rats.1999 · Szumlinski KK, Maisonneuve IM, Glick SD.Psychopharmacology (Berl) · MED 10463325 · DOI 10.1007/s002130051053
• Noribogaine generalization to the ibogaine stimulus: correlation with noribogaine concentration in rat brain.1999 · Zubaran C, Shoaib M, Stolerman IP, Pablo J, Mash DC.Neuropsychopharmacology · MED 10379526 · DOI 10.1016/s0893-133x(99)00003-2
• Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine.1999 · Fryer JD, Lukas RJ.J Pharmacol Exp Ther · MED 9862757 · DOI 10.1016/s0022-3565(24)37928-5
• NORIBOGAINE IN THE TREATMENT OF PAIN AND DRUG ADDICTION1999 · MASH Deborah C..Support non renseigné dans l’index · PAT WO9911250
• Long-term stability of abused drugs and antiabuse chemotherapeutical agents stored at -20 degrees C.1999 · Moody DE, Monti KM, Spanbauer AC.J Anal Toxicol · MED 10517563 · DOI 10.1093/jat/23.6.535
• Ibogaine pretreatment dramatically enhances the dynorphin response to cocaine.1999 · Alburges ME, Hanson GR.Brain Res · MED 10564747 · DOI 10.1016/s0006-8993(99)02017-x
• Ibogaine enhances the expression of locomotor sensitization in rats chronically treated with cocaine.1999 · Szumlinski KK, Maisonneuve IM, Glick SD.Pharmacol Biochem Behav · MED 10418788 · DOI 10.1016/s0091-3057(99)00038-6
• Ibogaine blocked methamphetamine-induced hyperthermia and induction of heat shock protein in mice.1999 · Yu X, Imam SZ, Newport GD, Slikker W, Ali SF.Brain Res · MED 10095030 · DOI 10.1016/s0006-8993(99)01154-3
• Further investigations of the serotonergic properties of the ibogaine-induced discriminative stimulus.1999 · Helsley S, Rabin RA, Winter JC.Prog Neuropsychopharmacol Biol Psychiatry · MED 10368872 · DOI 10.1016/s0278-5846(98)00101-8
• Differential responses by neurotensin systems in extrapyramidal and limbic structures to ibogaine and cocaine.1999 · Alburges ME, Hanson GR.Brain Res · MED 9914442 · DOI 10.1016/s0006-8993(98)01206-2
• Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice.1999 · Geter-Douglass B, Witkin JM.Psychopharmacology (Berl) · MED 10541728 · DOI 10.1007/s002130051118
• Attenuation of the reinforcing efficacy of morphine by 18-methoxycoronaridine.1999 · Maisonneuve IM, Glick SD.Eur J Pharmacol · MED 10556676 · DOI 10.1016/s0014-2999(99)00560-9
• Acute ibogaine injection induces expression of the immediate early genes, egr-1 and c-fos, in mouse brain.1999 · Ali SF, Thiriet N, Zwiller J.Brain Res Mol Brain Res · MED 10640697 · DOI 10.1016/s0169-328x(99)00283-1
• The effects of sigma, PCP, and opiate receptor ligands in rats trained with ibogaine as a discriminative stimulus.1998 · Helsley S, Filipink RA, Bowen WD, Rabin RA, Winter JC.Pharmacol Biochem Behav · MED 9477000 · DOI 10.1016/s0091-3057(97)00454-1
• The effects of beta-carbolines in rats trained with ibogaine as a discriminative stimulus.1998 · Helsley S, Rabin RA, Winter JC.Eur J Pharmacol · MED 9600629 · DOI 10.1016/s0014-2999(98)00002-8
• The Neurochemistry of Drugs of Abuse: Cocaine, Ibogaine, and Substituted Amphetamines. Proceedings of a meeting. Hamilton, Bermuda, July 16-18, 1997.1998 · Auteurs non renseignés dans l’indexAnn N Y Acad Sci · MED 9705733
• Observations on treatment with ibogaine.1998 · Luciano D.Am J Addict · MED 9522011 · DOI 10.1111/j.1521-0391.1998.tb00472.x
• Noribogaine stimulates naloxone-sensitive [35S]GTPgammaS binding.1998 · Pablo JP, Mash DC.Neuroreport · MED 9592058 · DOI 10.1097/00001756-199801050-00022
• Neurochemical and Neuroendocrine Effects of Ibogaine in Rats: Comparison to MK-801.1998 · Baumann MH, Rothman RB, Ali SF.Ann N Y Acad Sci · MED 29090818 · DOI 10.1111/j.1749-6632.1998.tb08240.x
• Modulation of the neuronal response to N-methyl-D-aspartate by selective sigma2 ligands.1998 · Couture S, Debonnel G.Synapse · MED 9552175 · DOI 10.1002/(sici)1098-2396(199805)29:1<62::aid-syn5>3.0.co;2-9
• Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.1998 · Efange SM, Mash DC, Khare AB, Ouyang Q.J Med Chem · MED 9804688 · DOI 10.1021/jm980156y
• Medication Development of Ibogaine as a Pharmacotherapy for Drug Dependence^a.1998 · Mash DC, Kovera CA, Buck BE, Norenberg MD, Shapshak P, Hearn WL, Sanchez-Ramos J.Ann N Y Acad Sci · MED 29090804 · DOI 10.1111/j.1749-6632.1998.tb08242.x
• Mechanisms of Antiaddictive Actions of Ibogaine^a.1998 · Glick SD, Maisonneuve IM.Ann N Y Acad Sci · MED 29090809 · DOI 10.1111/j.1749-6632.1998.tb08237.x
• In Vivo Ibogaine Blockade and In Vitro PKC Action of Cocaine^a.1998 · Onaivi ES, Ali SF, Chakrabarti A.Ann N Y Acad Sci · MED 29090806 · DOI 10.1111/j.1749-6632.1998.tb08238.x
• Ibogaine acts at the nicotinic acetylcholine receptor to inhibit catecholamine release.1998 · Mah SJ, Tang Y, Liauw PE, Nagel JE, Schneider AS.Brain Res · MED 9630615 · DOI 10.1016/s0006-8993(98)00207-8
• Gender differences in kappa-opioid modulation of cocaine-induced behavior and NMDA-evoked dopamine release.1998 · Sershen H, Hashim A, Lajtha A.Brain Res · MED 9729284 · DOI 10.1016/s0006-8993(98)00546-0
• Failure of ibogaine to produce phencyclidine-like discriminative stimulus effects in rats and monkeys.1998 · Jones HE, Li H, Balster RL.Pharmacol Biochem Behav · MED 9476989 · DOI 10.1016/s0091-3057(97)00452-8
• Enhancement of morphine antinociception by ibogaine and noribogaine in morphine-tolerant mice.1998 · Sunder Sharma S, Bhargava HN.Pharmacology · MED 9742287 · DOI 10.1159/000028246
• Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats.1998 · Rho B, Glick SD.Neuroreport · MED 9631413 · DOI 10.1097/00001756-199805110-00004
• Effect of ibogaine on the various sites of the NMDA receptor complex and sigma binding sites in rat brain.1998 · Itzhak Y, Ali SF.Ann N Y Acad Sci · MED 9668682 · DOI 10.1111/j.1749-6632.1998.tb08239.x
• Determination of common drugs of abuse in body fluids using one isolation procedure and liquid chromatography--atmospheric-pressure chemical-ionization mass spectromery.1998 · Bogusz MJ, Maier RD, Krüger KD, Kohls U.J Anal Toxicol · MED 9847004 · DOI 10.1093/jat/22.7.549
• Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine.1998 · Obach RS, Pablo J, Mash DC.Drug Metab Dispos · MED 9698290
• Behavioral and biochemical evidence for a nonessential 5-HT2A component of the ibogaine-induced discriminative stimulus.1998 · Helsley S, Fiorella D, Rabin RA, Winter JC.Pharmacol Biochem Behav · MED 9476990 · DOI 10.1016/s0091-3057(97)00451-6
• Antimycobacterial activity of chemically defined natural substances from the Caribbean flora in Guadeloupe.1998 · Rastogi N, Abaul J, Goh KS, Devallois A, Philogène E, Bourgeois P.FEMS Immunol Med Microbiol · MED 9626931 · DOI 10.1111/j.1574-695x.1998.tb01136.x
• Alteration of electroencephalogram and monoamine concentrations in rat brain following ibogaine treatment.1998 · Binienda Z, Beaudoin MA, Thorn BT, Prapurna DR, Johnson JR, Fogle CM, Slikker W, Ali SF.Ann N Y Acad Sci · MED 9668684 · DOI 10.1111/j.1749-6632.1998.tb08241.x
• Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats.1998 · Wei D, Maisonneuve IM, Kuehne ME, Glick SD.Brain Res · MED 9685673 · DOI 10.1016/s0006-8993(98)00527-7
• 18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats.1998 · Glick SD, Maisonneuve IM, Visker KE, Fritz KA, Bandarage UK, Kuehne ME.Psychopharmacology (Berl) · MED 9784085 · DOI 10.1007/s002130050716
• Use of ibogaine in reducing excitotoxic brain damage1997 · OLNEY JOHN W.Support non renseigné dans l’index · PAT US5629307
• Time-dependent interactions between iboga agents and cocaine.1997 · Maisonneuve IM, Visker KE, Mann GL, Bandarage UK, Kuehne ME, Glick SD.Eur J Pharmacol · MED 9384223 · DOI 10.1016/s0014-2999(97)01231-4
• The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity.1997 · O'Hearn E, Molliver ME.J Neurosci · MED 9348351 · DOI 10.1523/jneurosci.17-22-08828.1997
• The effects of noribogaine and harmaline in rats trained with ibogaine as a discriminative stimulus.1997 · Helsley S, Rabin RA, Winter JC.Life Sci · MED 9048970 · DOI 10.1016/s0024-3205(96)00703-5
• TRICYCLIC IBOGAINE ANALOGS, THEIR PREPARATION AND THEIR USE IN TREATING SUBSTANCE ABUSE1997 · EFANGE S. Mbua Ngale, MASH Deborah Carmen.Support non renseigné dans l’index · PAT WO9720847
• Sex differences in ibogaine antagonism of morphine-induced locomotor activity and in ibogaine brain levels and metabolism.1997 · Pearl SM, Hough LB, Boyd DL, Glick SD.Pharmacol Biochem Behav · MED 9259010 · DOI 10.1016/s0091-3057(96)00383-8
• Serotonergic mediation of fenfluramine discriminative stimuli in fawn-hooded rats.1997 · Schechter MD.Life Sci · MED 9031690
• Ibogaine: a potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors.1997 · Badio B, Padgett WL, Daly JW.Mol Pharmacol · MED 9016339 · DOI 10.1124/mol.51.1.1
• Ibogaine interferes with the establishment of amphetamine place preference learning.1997 · Moroz I, Parker LA, Siegel S.Exp Clin Psychopharmacol · MED 9234047 · DOI 10.1037//1064-1297.5.2.119
• Ibogaine effects on sweet preference and amphetamine induced locomotion: implications for drug addiction.1997 · Blackburn JR, Szumlinski KK.Behav Brain Res · MED 9475618 · DOI 10.1016/s0166-4328(97)00050-8
• Ibogaine and the dopaminergic response to nicotine.1997 · Maisonneuve IM, Mann GL, Deibel CR, Glick SD.Psychopharmacology (Berl) · MED 9084063 · DOI 10.1007/s002130050187
• Ibogaine and cocaine abuse: pharmacological interactions at dopamine and serotonin receptors.1997 · Sershen H, Hashim A, Lajtha A.Brain Res Bull · MED 8995326 · DOI 10.1016/s0361-9230(96)00296-1
• Ibogaine and a total alkaloidal extract of Voacanga africana modulate neuronal excitability and synaptic transmission in the rat parabrachial nucleus in vitro.1997 · Kombian SB, Saleh TM, Fiagbe NI, Chen X, Akabutu JJ, Buolamwini JK, Pittman QJ.Brain Res Bull · MED 9365804 · DOI 10.1016/s0361-9230(97)00284-0
• Excitotoxic mechanisms of neurodegeneration in transmissible spongiform encephalopathies.1997 · Scallet AC, Ye X.Ann N Y Acad Sci · MED 9369987 · DOI 10.1111/j.1749-6632.1997.tb48429.x
• Evidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine.1997 · Glick SD, Maisonneuve IM, Pearl SM.Brain Res · MED 9138735 · DOI 10.1016/s0006-8993(96)01414-x
• Effects of noribogaine on the development of tolerance to antinociceptive action of morphine in mice.1997 · Bhargava HN, Cao YJ.Brain Res · MED 9401754 · DOI 10.1016/s0006-8993(97)00914-1
• Effects of ibogaine on the development of tolerance to antinociceptive action of mu-, delta- and kappa-opioid receptor agonists in mice.1997 · Cao YJ, Bhargava HN.Brain Res · MED 9106464 · DOI 10.1016/s0006-8993(96)01470-9
• Effects of ibogaine on performance in the 8-arm radial maze.1997 · Helsley S, Fiorella D, Rabin RA, Winter JC.Pharmacol Biochem Behav · MED 9264067 · DOI 10.1016/s0091-3057(96)00476-5
• Effects of ibogaine and noribogaine on the antinociceptive action of mu-, delta- and kappa-opioid receptor agonists in mice.1997 · Bhargava HN, Cao YJ, Zhao GM.Brain Res · MED 9106462 · DOI 10.1016/s0006-8993(96)01461-8
• Effects of chronic ibogaine treatment on cerebellar Purkinje cells in the rat.1997 · Helsley S, Dlugos CA, Pentney RJ, Rabin RA, Winter JC.Brain Res · MED 9221953 · DOI 10.1016/s0006-8993(97)00365-x
• Bioactive tricyclic ibogaine analogs1997 · EFANGE S MBUA N, MASH DEBORAH C.Support non renseigné dans l’index · PAT US5616575
• Attenuation of alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats.1997 · Rezvani AH, Overstreet DH, Yang Y, Maisonneuve IM, Bandarage UK, Kuehne ME, Glick SD.Pharmacol Biochem Behav · MED 9300627 · DOI 10.1016/s0091-3057(97)10003-x
• Assessment of neurotoxicity from potential medications for drug abuse: ibogaine testing and brain imaging.1997 · Vocci FJ, London ED.Ann N Y Acad Sci · MED 9237447 · DOI 10.1111/j.1749-6632.1997.tb46187.x
• A METHOD OF TREATING CHEMICAL DEPENDENCY IN MAMMALS AND A COMPOSITION THEREFOR1997 · MASH Deborah C.-Univ. of Miami-Dept. of Neurol., SANCHEZ-RAMOS Juan University of Miami, HEARN W.Lee.Support non renseigné dans l’index · PAT EP0804200
• Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration.1996 · Hough LB, Pearl SM, Glick SD.Life Sci · MED 8632705 · DOI 10.1016/0024-3205(95)02322-4
• The effect of ibogaine on Sigma- and NMDA-receptor-mediated release of [3H]dopamine.1996 · Sershen H, Hashim A, Lajtha A.Brain Res Bull · MED 8722755 · DOI 10.1016/0361-9230(96)00039-1
• Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors.1996 · Layer RT, Skolnick P, Bertha CM, Bandarage UK, Kuehne ME, Popik P.Eur J Pharmacol · MED 8874134 · DOI 10.1016/0014-2999(96)00304-4
• Prior morphine exposure enhances ibogaine antagonism of morphine-induced dopamine release in rats.1996 · Pearl SM, Maisonneuve IM, Glick SD.Neuropharmacology · MED 9076757 · DOI 10.1016/s0028-3908(96)00116-5
• Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine.1996 · Staley JK, Ouyang Q, Pablo J, Hearn WL, Flynn DD, Rothman RB, Rice KC, Mash DC.Psychopharmacology (Berl) · MED 8880938 · DOI 10.1007/bf02805969
• Neuropharmacological characterization of local ibogaine effects on dopamine release.1996 · Reid MS, Hsu K, Souza KH, Broderick PA, Berger SP.J Neural Transm (Vienna) · MED 9013390 · DOI 10.1007/bf01291787
• Neuroendocrine and neurochemical effects of acute ibogaine administration: a time course evaluation.1996 · Ali SF, Newport GD, Slikker W, Rothman RB, Baumann MH.Brain Res · MED 8930368 · DOI 10.1016/0006-8993(96)00734-2
• Neurochemical and behavioural interactions between ibogaine and nicotine in the rat.1996 · Benwell ME, Holtom PE, Moran RJ, Balfour DJ.Br J Pharmacol · MED 8646423 · DOI 10.1111/j.1476-5381.1996.tb15253.x
• NOS and fos in rat and mouse brain regions. Possible relation to ibogaine-induced Purkinje cell loss.1996 · Scallet AC, Ye X, Ali SF.Ann N Y Acad Sci · MED 8959037 · DOI 10.1111/j.1749-6632.1996.tb17445.x
• Modulation of morphine-induced antinociception by ibogaine and noribogaine.1996 · Bagal AA, Hough LB, Nalwalk JW, Glick SD.Brain Res · MED 9001731 · DOI 10.1016/s0006-8993(96)00938-9
• Ibogaine-like effects of noribogaine in rats.1996 · Glick SD, Pearl SM, Cai J, Maisonneuve IM.Brain Res · MED 8725004 · DOI 10.1016/0006-8993(95)01563-9
• Ibogaine selectively inhibits nicotinic receptor-mediated catecholamine release.1996 · Schneider AS, Nagel JE, Mah SJ.Eur J Pharmacol · MED 8997631 · DOI 10.1016/s0014-2999(96)00815-1
• Ibogaine produces neurodegeneration in rat, but not mouse, cerebellum. Neurohistological biomarkers of Purkinje cell loss.1996 · Scallet AC, Ye X, Rountree R, Nony P, Ali SF.Ann N Y Acad Sci · MED 8959036 · DOI 10.1111/j.1749-6632.1996.tb17444.x
• Ibogaine neurotoxicity: a re-evaluation.1996 · Molinari HH, Maisonneuve IM, Glick SD.Brain Res · MED 8930373 · DOI 10.1016/0006-8993(96)00739-1
• Ibogaine fails to interrupt the expression of a previously established one-trial morphine place preference.1996 · Luxton T, Parker LA, Siegel S.Prog Neuropsychopharmacol Biol Psychiatry · MED 8870069 · DOI 10.1016/0278-5846(96)00064-4
• Ibogaine block of the NMDA receptor: in vitro and in vivo studies.1996 · Chen K, Kokate TG, Donevan SD, Carroll FI, Rogawski MA.Neuropharmacology · MED 8793904 · DOI 10.1016/0028-3908(96)84107-4
• Ibogaine and noribogaine potentiate the inhibition of adenylyl cyclase activity by opioid and 5-HT receptors.1996 · Rabin RA, Winter JC.Eur J Pharmacol · MED 8982706 · DOI 10.1016/s0014-2999(96)00690-5
• Facilitation of memory retrieval by the "anti-addictive" alkaloid, ibogaine.1996 · Popik P.Life Sci · MED 8950313 · DOI 10.1016/s0024-3205(96)00564-4
• Effects of ibogaine, and cocaine and morphine after ibogaine, on ventral tegmental dopamine neurons.1996 · French ED, Dillon K, Ali SF.Life Sci · MED 8809219 · DOI 10.1016/0024-3205(96)00412-2
• Effects of ibogaine and noribogaine on phosphoinositide hydrolysis.1996 · Rabin RA, Winter JC.Brain Res · MED 8883876 · DOI 10.1016/0006-8993(96)00688-9
• Effect of ibogaine on cocaine-induced efflux of [3H] dopamine and [3H] serotonin from mouse striatum.1996 · Sershen H, Hashim A, Lajtha A.Pharmacol Biochem Behav · MED 8801590 · DOI 10.1016/0091-3057(95)02098-5
• Determination of ibogaine in plasma by gas chromatography--chemical ionization mass spectrometry.1996 · Ley FR, Jeffcoat AR, Thomas BF.J Chromatogr A · MED 8819825 · DOI 10.1016/0021-9673(95)00827-6
• Cellular and Molecular Mechanisms of Drugs of Abuse: Cocaine, Ibogaine, and Substituted Amphetamines. Proceedings of a conference. Niigata City, Japan, June 29-30, 1995.1996 · Auteurs non renseignés dans l’indexAnn N Y Acad Sci · MED 9729221
• Acute and chronic administration of ibogaine to the rat results in astrogliosis that is not confined to the cerebellar vermis.1996 · O'Callaghan JP, Rogers TS, Rodman LE, Page JG.Ann N Y Acad Sci · MED 8959035 · DOI 10.1111/j.1749-6632.1996.tb17443.x
• A METHOD OF TREATING CHEMICAL DEPENDENCY IN MAMMALS AND A COMPOSITION THEREFOR1996 · MASH Deborah C., SANCHEZ-RAMOS Juan, HEARN W. Lee.Support non renseigné dans l’index · PAT WO9603127
• 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats.1996 · Glick SD, Kuehne ME, Maisonneuve IM, Bandarage UK, Molinari HH.Brain Res · MED 8782860 · DOI 10.1016/0006-8993(96)00056-x
• The effect of ibogaine on kappa-opioid- and 5-HT3-induced changes in stimulation-evoked dopamine release in vitro from striatum of C57BL/6By mice.1995 · Sershen H, Hashim A, Lajtha A.Brain Res Bull · MED 7757494 · DOI 10.1016/0361-9230(94)00250-5
• Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity.1995 · Sweetnam PM, Lancaster J, Snowman A, Collins JL, Perschke S, Bauer C, Ferkany J.Psychopharmacology (Berl) · MED 7568622 · DOI 10.1007/bf02245936
• Radioligand-binding study of noribogaine, a likely metabolite of ibogaine.1995 · Pearl SM, Herrick-Davis K, Teitler M, Glick SD.Brain Res · MED 7796150 · DOI 10.1016/0006-8993(95)00123-8
• Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex.1995 · Mash DC, Staley JK, Pablo JP, Holohean AM, Hackman JC, Davidoff RA.Neurosci Lett · MED 7675310 · DOI 10.1016/0304-3940(95)11608-y
• Prior morphine exposure enhances ibogaine antagonism of morphine-induced locomotor stimulation.1995 · Pearl SM, Johnson DW, Glick SD.Psychopharmacology (Berl) · MED 8619010 · DOI 10.1007/bf02246495
• NMDA antagonist properties of the putative antiaddictive drug, ibogaine.1995 · Popik P, Layer RT, Fossom LH, Benveniste M, Geter-Douglass B, Witkin JM, Skolnick P.J Pharmacol Exp Ther · MED 7473163 · DOI 10.1016/s0022-3565(25)12125-3
• Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin.1995 · Mash DC, Staley JK, Baumann MH, Rothman RB, Hearn WL.Life Sci · MED 7596224 · DOI 10.1016/0024-3205(95)00273-9
• Identification and quantitation of ibogaine and an o-demethylated metabolite in brain and biological fluids using gas chromatography-mass spectrometry.1995 · Hearn WL, Pablo J, Hime GW, Mash DC.J Anal Toxicol · MED 8926737 · DOI 10.1093/jat/19.6.427
• Identification and quantification of the indole alkaloid ibogaine in biological samples by gas chromatography-mass spectrometry.1995 · Gallagher CA, Hough LB, Keefner SM, Seyed-Mozaffari A, Archer S, Glick SD.Biochem Pharmacol · MED 7840786 · DOI 10.1016/0006-2952(94)00441-n
• Ibogaine possesses a selective affinity for sigma 2 receptors.1995 · Mach RH, Smith CR, Childers SR.Life Sci · MED 7603301 · DOI 10.1016/0024-3205(95)00301-l
• Ibogaine and its congeners are sigma 2 receptor-selective ligands with moderate affinity.1995 · Bowen WD, Vilner BJ, Williams W, Bertha CM, Kuehne ME, Jacobson AE.Eur J Pharmacol · MED 7556375 · DOI 10.1016/0014-2999(95)00247-i
• High affinity ibogaine binding to a mu opioid agonist site.1995 · Codd EE.Life Sci · MED 7475926 · DOI 10.1016/0024-3205(95)02171-e
• Excitotoxic insult due to ibogaine leads to delayed induction of neuronal NOS in Purkinje cells.1995 · O'Hearn E, Zhang P, Molliver ME.Neuroreport · MED 8527725 · DOI 10.1097/00001756-199508000-00006
• Effects of ibogaine on sensory-motor function, activity, and spatial learning in rats.1995 · Kesner RP, Jackson-Smith P, Henry C, Amann K.Pharmacol Biochem Behav · MED 7617719 · DOI 10.1016/0091-3057(94)00367-r
• Effects of ibogaine on responding maintained by food, cocaine and heroin reinforcement in rats.1995 · Dworkin SI, Gleeson S, Meloni D, Koves TR, Martin TJ.Psychopharmacology (Berl) · MED 7770600 · DOI 10.1007/bf02246099
• Discriminative stimulus effects of R-(+)-3-amino-1-hydroxypyrrolid-2-one, [(+)-HA-966], a partial agonist of the strychnine-insensitive modulatory site of the N-methyl-D-aspartate receptor.1995 · Witkin JM, Brave S, French D, Geter-Douglass B.J Pharmacol Exp Ther · MED 8531091 · DOI 10.1016/s0022-3565(25)12180-0
• Determination of ibogaine and 12-hydroxy-ibogamine in plasma by gas chromatography-positive ion chemical ionization-mass spectrometry.1995 · Alburges ME, Foltz RL, Moody DE.J Anal Toxicol · MED 8926731 · DOI 10.1093/jat/19.6.381
• Comparison of the hallucinogenic indole alkaloids ibogaine and harmaline for potential immunomodulatory activity.1995 · House RV, Thomas PT, Bhargava HN.Pharmacology · MED 7568345 · DOI 10.1159/000139317
• Attenuation of alcohol intake by ibogaine in three strains of alcohol-preferring rats.1995 · Rezvani AH, Overstreet DH, Lee YW.Pharmacol Biochem Behav · MED 8545483 · DOI 10.1016/0091-3057(95)00152-m
• 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug.1995 · Popik P, Layer RT, Skolnick P.Pharmacol Rev · MED 7568327 · DOI 10.1016/s0031-6997(25)06842-5
• The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complex.1994 · Popik P, Layer RT, Skolnick P.Psychopharmacology (Berl) · MED 7531855 · DOI 10.1007/bf02245000
• The inhibitory effect of norharman on morphine withdrawal syndrome in rats: comparison with ibogaine.1994 · Cappendijk SL, Fekkes D, Dzoljic MR.Behav Brain Res · MED 7880450 · DOI 10.1016/0166-4328(94)90080-9
• Ibogaine reduces preference for cocaine consumption in C57BL/6By mice.1994 · Sershen H, Hashim A, Lajtha A.Pharmacol Biochem Behav · MED 8115413 · DOI 10.1016/0091-3057(94)90105-8
• Ibogaine modulates cocaine responses which are altered due to environmental habituation: in vivo microvoltammetric and behavioral studies.1994 · Broderick PA, Phelan FT, Eng F, Wechsler RT.Pharmacol Biochem Behav · MED 7862728 · DOI 10.1016/0091-3057(94)90092-2
• Evidence that ibogaine releases dopamine from the cytoplasmic pool in isolated mouse striatum.1994 · Harsing LG, Sershen H, Lajtha A.J Neural Transm Gen Sect · MED 7826572 · DOI 10.1007/bf01294788
• Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum.1994 · Glick SD, Kuehne ME, Raucci J, Wilson TE, Larson D, Keller RW, Carlson JN.Brain Res · MED 7820611 · DOI 10.1016/0006-8993(94)90948-2
• Effect of ibogaine on serotonergic and dopaminergic interactions in striatum from mice and rats.1994 · Sershen H, Hashim A, Lajtha A.Neurochem Res · MED 7898613 · DOI 10.1007/bf00972476
• A preliminary investigation of ibogaine: case reports and recommendations for further study.1994 · Sheppard SG.J Subst Abuse Treat · MED 7966509 · DOI 10.1016/0740-5472(94)90049-3
• Local effects of ibogaine on extracellular levels of dopamine and its metabolites in nucleus accumbens and striatum: interactions with D-amphetamine.1993 · Glick SD, Rossman K, Wang S, Dong N, Keller RW.Brain Res · MED 8313148 · DOI 10.1016/0006-8993(93)90956-n
• Inhibitory effects of ibogaine on cocaine self-administration in rats.1993 · Cappendijk SL, Dzoljic MR.Eur J Pharmacol · MED 8243561 · DOI 10.1016/0014-2999(93)90212-z
• Ibogaine induces glial activation in parasagittal zones of the cerebellum.1993 · O'Hearn E, Long DB, Molliver ME.Neuroreport · MED 8477052 · DOI 10.1097/00001756-199303000-00018
• Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline.1993 · O'Hearn E, Molliver ME.Neuroscience · MED 8377927 · DOI 10.1016/0306-4522(93)90500-f
• Comparison of the behavioral effects of ibogaine from three sources: mediation of discriminative activity.1993 · Schechter MD, Gordon TL.Eur J Pharmacol · MED 8282022 · DOI 10.1016/0014-2999(93)90664-4
• Cocaine discrimination is attenuated by isradipine and CGS 10746B.1993 · Schechter MD.Pharmacol Biochem Behav · MED 8095726 · DOI 10.1016/0091-3057(93)90183-t
• Stimulus effects of ibogaine in rats trained with yohimbine, DOM, or LSD.1992 · Palumbo PA, Winter JC.Pharmacol Biochem Behav · MED 1475306 · DOI 10.1016/0091-3057(92)90506-b
• Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies.1992 · Deecher DC, Teitler M, Soderlund DM, Bornmann WG, Kuehne ME, Glick SD.Brain Res · MED 1377086 · DOI 10.1016/0006-8993(92)90661-r
• Interactions of ibogaine and D-amphetamine: in vivo microdialysis and motor behavior in rats.1992 · Maisonneuve IM, Keller RW, Glick SD.Brain Res · MED 1623410 · DOI 10.1016/0006-8993(92)90745-u
• Interactions between ibogaine and cocaine in rats: in vivo microdialysis and motor behavior.1992 · Maisonneuve IM, Glick SD.Eur J Pharmacol · MED 1601069 · DOI 10.1016/0014-2999(92)90340-a
• Ibogaine reduces amphetamine-induced locomotor stimulation in C57BL/6By mice, but stimulates locomotor activity in rats.1992 · Sershen H, Harsing LG, Hashim A, Lajtha A.Life Sci · MED 1522749 · DOI 10.1016/0024-3205(92)90498-e
• Ibogaine antagonizes cocaine-induced locomotor stimulation in mice.1992 · Sershen H, Hashim A, Harsing L, Lajtha A.Life Sci · MED 1556903 · DOI 10.1016/0024-3205(92)90344-o
• Effects of ibogaine on naloxone-precipitated withdrawal in morphine-dependent mice.1992 · Francés B, Gout R, Cros J, Zajac JM.Fundam Clin Pharmacol · MED 1292965 · DOI 10.1111/j.1472-8206.1992.tb00127.x
• Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor.1992 · Glick SD, Rossman K, Rao NC, Maisonneuve IM, Carlson JN.Neuropharmacology · MED 1528400 · DOI 10.1016/0028-3908(92)90089-8
• Differential effects of ibogaine pretreatment on brain levels of morphine and (+)-amphetamine.1992 · Glick SD, Gallagher CA, Hough LB, Rossman KL, Maisonneuve IM.Brain Res · MED 1393568 · DOI 10.1016/0006-8993(92)91360-q
• Acute and prolonged effects of ibogaine on brain dopamine metabolism and morphine-induced locomotor activity in rats.1992 · Maisonneuve IM, Rossman KL, Keller RW, Glick SD.Brain Res · MED 1504783 · DOI 10.1016/0006-8993(92)90424-8
• A RAPID METHOD FOR INTERRUPTING OR ATTENUATING POLY-DRUG DEPENDENCY SYNDROMES1992 · LOTSOF Howard S..Support non renseigné dans l’index · PAT EP0511325
• 1992 · LOTSOF HOWARD S.Support non renseigné dans l’index · PAT US5152994
• Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome1991 · LOTSOF HOWARD S.Support non renseigné dans l’index · PAT US5026697
• Interactions between ibogaine, a potential anti-addictive agent, and morphine: an in vivo microdialysis study.1991 · Maisonneuve IM, Keller RW, Glick SD.Eur J Pharmacol · MED 1893925 · DOI 10.1016/0014-2999(91)90634-3
• Effects and aftereffects of ibogaine on morphine self-administration in rats.1991 · Glick SD, Rossman K, Steindorf S, Maisonneuve IM, Carlson JN.Eur J Pharmacol · MED 1868880 · DOI 10.1016/0014-2999(91)90474-5
• A RAPID METHOD FOR INTERRUPTING OR ATTENUATING POLY-DRUG DEPENDENCY SYNDROMES1991 · LOTSOF Howard S..Support non renseigné dans l’index · PAT WO9118609
• Ibogaine fails to reduce naloxone-precipitated withdrawal in the morphine-dependent rat.1990 · Sharpe LG, Jaffe JH.Neuroreport · MED 2129850 · DOI 10.1097/00001756-199009000-00005
• Ibogaine fails to reduce naloxone-precipitated withdrawal in the morphine dependent rat.1990 · Sharpe L, Jaffe J.NIDA Res Monogr · MED 1876088
• Rapid method for attenuating the alcohol dependency syndrome1989 · LOTSOF HOWARD S.Support non renseigné dans l’index · PAT US4857523
• Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats.1988 · Dzoljic ED, Kaplan CD, Dzoljic MR.Arch Int Pharmacodyn Ther · MED 3233054
• Neocortical rhythmic slow activity during wakefulness and paradoxical sleep in rats.1987 · Depoortere H.Neuropsychobiology · MED 3453433 · DOI 10.1159/000118411
• Rapid method for interrupting the cocaine and amphetamine abuse syndrome1986 · LOTSOF HOWARD S.Support non renseigné dans l’index · PAT US4587243
• Rapid method for interrupting the narcotic addiction syndrome1985 · LOTSOF HOWARD S.Support non renseigné dans l’index · PAT US4499096
• Phytochemical investigation of Tabernaemontana crassa.1985 · van Beek TA, de Smidt C, Verpoorte R.J Ethnopharmacol · MED 4094474 · DOI 10.1016/0378-8741(85)90096-0
• A RAPID METHOD FOR INTERRUPTING THE NARCOTIC ADDICTION SYNDROME1985 · LOTSOF Howard S..Support non renseigné dans l’index · PAT EP0163697
• A RAPID METHOD FOR INTERRUPTING THE NARCOTIC ADDICTION SYNDROME1985 · LOTSOF Howard S..Support non renseigné dans l’index · PAT WO8502115
• Indole alkaloids from cell suspension cultures of Tabernaemontana divaricata and Tabernanthe iboga.1983 · Pawelka KH, Stöckigt J.Plant Cell Rep · MED 24257961 · DOI 10.1007/bf00270178
• Cholecystokinin octapeptide (CCK-8), ceruletide and analogues of ceruletide: effects on tremors induced by oxotremorine, harmine and ibogaine. A comparison with prolyl-leucylglycine amide (MIF), anti-Parkinsonian drugs and clonazepam.1983 · Zetler G.Neuropharmacology · MED 6310434 · DOI 10.1016/0028-3908(83)90100-4
• [Modification of awake-sleep equilibrium by tabernanthine and some of its derivatives in the cat (author's transl)].1980 · Da Costa L, Sulklaper I, Naquet R.Rev Electroencephalogr Neurophysiol Clin · MED 7465937 · DOI 10.1016/s0370-4475(80)80027-x
• [The effect of alkaloids from Tabernanthe iboga H. Bn. on the response of isolated organs to catecholamines and the possible role of calcium exchange. Case of Ibogaine].1977 · Valette G, Leclair MF.C R Acad Hebd Seances Acad Sci D · MED 413652
• [Effects of Tabermanthe iboga H. Bn. alkaloids on the isolated organ responses to catecholamines and the role of calcium exchanges. Tabernanthine].1977 · Valette G, Leclair MF.C R Acad Hebd Seances Acad Sci D · MED 410542
• [Detection of ibogaine in organic liquids].1976 · Bertol E, Mari F, Froldi R.J Chromatogr · MED 1249155 · DOI 10.1016/s0021-9673(00)81092-4
• [Indole alkaloids induction of tremors: effect on photosensible epilepsy in Papiopapio].1975 · Brailowsky S, Walter S, Vuillon-Cacciuttolo G, Serbanescu T.C R Seances Soc Biol Fil · MED 131611
• [Constituents of seeds of Tabernanthe iboga Baillon. I. Alkaloids].1974 · Goutarel R, Poisson J, Croquelois G, Rolland Y, Miet C.Ann Pharm Fr · MED 4462431
• The identification of ibogaine in biological material.1972 · Dhahir HI, Jain NC, Thornton JI.J Forensic Sci Soc · MED 5014089 · DOI 10.1016/s0015-7368(72)70681-7
• Gas chromatographic determination of ibogaine in biological fluids.1972 · Cartoni GP, Giarusso A.J Chromatogr · MED 5056243 · DOI 10.1016/s0021-9673(01)85700-9
• Methods for the detection and determination of ibogaine in biological materials.1971 · Dhahir HI, Jain NC, Forney RB.J Forensic Sci · MED 5103073
• [The psychic effect of ibogaline hydrochloride (alkaloid from Tabernanthe iboga Baill)].1967 · Schmid PB.Arzneimittelforschung · MED 5632444
• [Voacanga alkaloids. III. Voacristine: identity with voacangarine and decomposition to iboxygaine and ibogaine].1959 · RENNER U, PRINS DA.Experientia · MED 14437366 · DOI 10.1007/bf02158249
• [Titration of the total alkaloids in the roots of Tabernanthe iboga].1959 · GHIELMETTI G, MELA C.Farmaco Prat · MED 13630277
• The biogenesis of the Tabernanthe iboga alkaloids.1957 · TAYLOR WI.Experientia · MED 13501226 · DOI 10.1007/bf02157247
• Neuropharmacological studies on ibogaine, an indole alkaloid with central-stimulant properties.1957 · SCHNEIDER JA, SIGG EB.Ann N Y Acad Sci · MED 13425258 · DOI 10.1111/j.1749-6632.1957.tb40765.x
• Effects of LSD 25, BOL 148, bufotenine, mescaline and ibogaine on the potentiation of hexobarbital hypnosis produced by serotonin and reserpine.1957 · SALMOIRAGHI GC, PAGE IH.J Pharmacol Exp Ther · MED 13449697 · DOI 10.1016/s0022-3565(25)11810-7
• Analysis of the cardiovascular action of ibogaine hydrochloride.1957 · SCHNEIDER JA, RINEHART RK.Arch Int Pharmacodyn Ther · MED 13425751
• [Pharmacological effect and therapeutic properties of two tropical African plants: Tabernanthe Iboga H. Baillon and Tabernanthe Mannii Stapf].1956 · ROBIOLA PF.Gazz Med Ital · MED 13344888
• Potentiation action of ibogaine (bogadin TM) on morphine analgesia.1956 · MCARTHUR M, SCHNEIDER JA.Experientia · MED 13356821 · DOI 10.1007/bf02159638
• [Ibolutein, new alkaloid extracted from iboga (Tabernanthe iboga H. Bn, Apocynaceae)].1953 · GOUTAREL R, JANOT MM.Ann Pharm Fr · MED 13065910
• Of the physiological action of iboga, Tabernanthe iboga H. Bn., And of ibogaine; effect on muscle chronaxis.1949 · PARIS R, VAIREL C.C R Hebd Seances Acad Sci · MED 18117818